							5872130	
	PATEN	1985 1985	talan di Katana General di Katana	NUME?	ļ			l.
0.7/531,092 12/	19/90 1.2 60	s	UBCLASS	ф <i>у (ловы и и и и и и и и и и и и и и и и и и и</i>	GRO	upart unit -129 774 1.1	EXAMINER	
YOSHIH'RO FUJIKA Japan; Hiroshi I Shiraoka-Machi,	WASAKI, FUNAE	BASHI-S	HI, JA	APAN; I	MITSUA			1200- A.V.
CONTINUING DAT VERIFIED TH	A***********************************	****** CON 0	*** F 01	7/233,		/17/33		AFC .
Vertfied - AC	TARAN JARAM Metar JARAN	n, bind Krister is	. 6769. 1923 - 1973 1932 - 1973 1932 - 1973	1011 1940 34942		98730797 01736703 98738703	3	
	2							
Foreign priority claimed Vye 35 USC 119 conditions met Vye	s I no s I no AS FILED	STATE OR	SHEETS DRWGS.	CLAIMS	INDEP.	FILING FEE RECEIVED	ATTORNEY'S DOCKET NO.	
OBLINE OPTIAL MATUR & MULEIAN TWATTH FLOOP 1775 JEFFERSON ARLINGTON, VA	onera ensemble		1997 - 19		£		12 - 49 - 18 3 - 19 - 19	
in of the literate which is a literate of				u.s. dep	T. of COMM	-Pat. & TM Office	e — FTO-436L (rev. 10-7)	8)
Nama da su da s			1.100 To 14/16.000000000000000000000000000000000000		2			A share a second state
ARTS OF APPLICATION								and the second
DTICE OF ALLOWANCE MAILE	D PRE	PARED FOI	the second second second	1.0	Total C	CLAIMS A	LLOWED Print Claim	
9-30-18	Assistant Examiner	Boc	ket Clerk	sell	4	5		
ISSUE FEE TO ount Due Date Paid 320.00 (0/7/9)	Laure Laure	2 L. S 2 J.S	Stockt		Sheets	DRAV Drwg. Figs. D		1
		UE CLASS		nary Examin N	er ISSUE			-
Label	Class 514	the same sector with the secto	class 311		BATCH		RI	and the second second
Area	Possessi	d by the Unit	ted States ne U.S. Pate	Code Title 3	5. Sections	122, 181 and 368	disclosure may be 3, uthorized employees	
1 PTO-436 5/89		and the second secon	. Certri de contrate de de la con					
0.04								and the second
								- Alexandre

07. 631092

PATENT APPLICATION SERIAL NO.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

100 DL 01/03/91 07631092

PTO-1556 (5/87) 1 101 630.00 CK 49-146-0

~			H	U.S. 1	PATENT A	PPLICATION	
SERIAL N	UMBER		FI	LING DATE	CLASS	GROUP ART UNI	T
07/	631,09	32		12/19/90 RULE 60	546	129	
JAP	AN; H	ROSHI IWAS	AKI, FUNABA	SHI, JAPAN; M SHI—SHI, JAPAN KITAHARA, SHIN	N; MITSUAKI S.		20
			********* APPLN IS A	******* CON OF 07/2	33,752 08/19/	88	
	OREIGN		CATIONS****	e she she she she she she she she sh			
«	10		•				
TATE OF		SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS	FILING FEE RECEIVED	ATTORNEY DOCKET NO	
JP	x	0	2	11	\$ 630.00	49-146-0-CON	
MA F 0 1 7	URTH F 55 JEF		IS HIGHWAY				
QU	JINOLIN	IE [°] TYPE MEV	ALONOACTONE	S	2.1	10	
his is	to cer	tify that an	nexed hereto	is a true copy	from the record	ds of the United Sta	tes
atent a y autho	and Trad	demark Offic f the	e of the appl	lication as orig	inally filed w	nich is identified al	bove.
OMMISSI	ONER O	F PATENTS AN	D TRADEMARKS	Certifying Offic	D.		
ate					11		
ate							
Date		n ingen Sent			,	n e w	×
Date)/ e	× ci ti
Date					* 2	12 40 K 10 10	×
Date					*	н е. н н н	×

Sawai Ex 1003 Page 3 of 175

- Server

07 631092



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. _____ CONT

HONORABLE COMMISSIONER OF PATENTS & TRADEMARKS WASHINGTON, D.C. 20231

SIR: This is a request for filing a

X Continuation

application under 37 C.F.R. 1.60,

Division

Ĩ

of copending prior application Serial No.07/233,752 filed on AUGUST 19, 1988 of date YOSHIHIRO FUJIKAWA ET AL

title of invention

for QUINOLINE TYPE MENALONOLACTONES

- 1. X Enclosed is a copy of the prior application as originally filed and an affidavit or declaration verifying it as a true copy.
- 2. Small Entity Status of this application has been established by a Verified Statement submitted in the parent application.

3. X The filing fee is calculated below:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT BELOW

For	Number filed	Number extra		Rate	Basic \$63	Fee 0.00
Total Claims	1 –20	= - 0	x \$	20	=	0
Independent Claims	<u>1</u> –3	= 0	x\$	60		0
	Multi	ple Claim Fee	- \$	200	=	0
	Tota	Filing Fee			= \$	630

4. The Commissioner is hereby authorized to charge any fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Account No. <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

5. X A check in the amount of \$ 630.00 is enclosed.

6. X Cancel Claims 2-9 and 11-40

7. X Amend the specification by inserting before the first line the sentence:

This is a X continuation, _____ division, of application Serial No. 07/233,752 _ , filed on AUGUST 19, 1988

8. New Drawings are enclosed.

9. The prior application is assigned to:

- 10. X The Power of Attorney in the prior application is to: Norman F. Oblon, Reg. No. 24,618; Marvin J. Spivak, Reg. No. 24,913; C. Irvin McClelland, Reg. No. 21,124; Gregory J. Maier, Reg. No. 25,599; Arthur I. Neustadt, Reg. No. 24,854; Robert C. Miller, Reg. No. 25,357; Richard D. Kelly, Reg. No. 27,757; James D. Hamilton, Reg. No. 28,421; Eckhard H. Kuesters, Reg. No. 28,870; Robert T. Pous, Reg. No. 29,099; Charles L. Gholz, Reg. No. 26,395; Vincent J. Sunderdick, Reg. No. 29,004; William E. Beaumont, Reg. No. 30,996; Steve B. Kelber, Reg. No. 30,073; Stuart D. Dwork, Reg. No. 31,103; Robert F. Gnuse, Reg. No. 27,295; and Jean-Paul Lavalleye, Reg. No. 31,451, all of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.
 - a. X The power appears in the original papers of the prior application. (copy enclosed)
 - b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
 - c. Recognize as associate attorney and address all future communications to:

11. X A Preliminary Amendment is enclosed.

12. X Priority under \$120 is enclosed as well as Declaration of Steven B. Kelber. White Advance Serial Number Postal Card (postage prepaid) attached. Respectfully submitted,

name, registration number and address

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Black

Norman F. Oblon Attorney of Record Registration No. 24,618

Steven B. Kelber Attorney of Record Registration No. 30,073

FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 521-5940

4/89



501

07 631092

Our Ref.: NC-115

QUINOLINE TYPE MEVALONOLACTONES

The present invention relates to novel mevalonolactones having a quinoline ring, processes for their production, pharmaceutical compositions containing them and their pharmaceutical uses particularly as anti-hyperlipidemic, hypolipoproteinemic and anti-atherosclerotic agents, and intermediates useful for their production and processes for the production of such intermediates.

- 1 -

10

15

20

-

5

Some fermentation metabolic products such as compactine, CS-514, Mevinolin or semi-synthetic derivatives or fully synthetic derivatives thereof are known to be inhibitors against HMG-CoA reductase which is a rate limiting enzyme for cholesterol biosynthesis. (A. Endo J. Med Chem., 28(4) 401 (1985))

CS-514 and Mevinolin have been clinically proved to be potentially useful anti-hyperlipoproteinemic agents, and they are considered to be effective for curing or preventing diseases of coronary artery sclerosis or atherosclerosis. (IXth Int. Symp. Drugs Affect. Lipid Metab., 1986, p30, p31, p66)


However, with respect to fully synthetic derivatives, particularly hetero aromatic derivatives of inhibitors against HMG-CoA reductase, limited information is disclosed in the following literatures:

- 2 -

WPI ACC NO. 84-158675, 86-028274, 86-098816, 86-332070, 87-124519, 87-220987, 88-07781, 88-008460, 88-091798 and 88-112505.

The present inventors have found that mevalonolactone 10 derivatives having a quinoline ring, the corresponding dihydroxy carboxylic acids and salts and esters thereof have high inhibitory activities against cholesterol biosynthesis wherein HMG-CoA reductase acts as a rate limiting enzyme. The present invention has been 15 accomplished on the basis of this discovery.

The novel mevalonolactone derivatives of the present invention are represented by the following formula I:



Ro

1

5

(I)

wherein R^1 , R^2 , R^3 , R^4 and R^6 are independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkoxy, n-butoxy, 25 i-butoxy, sec-butoxy, $R^7 R^8 N$ - (wherein R^7 and R^8 are independently hydrogen or C_{1-3} alkyl), trifluoromethyl,

trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo,

phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or -O(CH₂)_lOR¹⁹ (wherein ${\rm R}^{19}$ is hydrogen or ${\rm C}_{1-3}$ alkyl, and ℓ is 1, 2 or 3); or when located at the ortho position to each other, R^1 and R^2 , or R^3 and R^4 together form -CH=CH-CH=CH-; or when located at the ortho position to each other, R^1 and R^2 together form $-OC(R^{15})(R^{16})O-$ (wherein R^{15} and R^{16} are independently hydrogen or C_{1-3} alkyl); Y is $-CH_2^-$, -CH₂CH₂-, -CH=CH-, -CH₂-CH=CH- or -CH=CH-CH₂-; and Z is -Q-CH2WCH2-CO2R12, 10


5

15

1

or

3 -



(wherein Q is -C(0)-, $-C(0R^{13})_2^{i}$ or -CH(0H)-; W is -C(0)-, $-C(OR^{13})_2$ or $-C(R^{11})(OH)$; R^{11} is hydrogen or C_{1-3} alkyl; R^{12} is hydrogen or R^{14} (wherein R^{14} is physiologically

hydrolyzable alkyl or M (wherein M is $NH_4^{}$, sodium, 20 potassium, 1/2 calcium or a hydrate of lower alkylamine, di-lower alkylamine or tri-lower alkylamine)); two R¹³ are independently primary or secondary C_{1-6} alkyl; or two R^{13} together form $-(CH_2)_2$ or $-(CH_2)_3$; R¹⁷ and R¹⁸ are

independently hydrogen or C_{1-3} alkyl; and R^5 is 25 hydrogen, C_{1-6} alkyl, C_{2-3} alkenyl, C_{3-6} cycloalkyl,

(wherein R^9 is hydrogen, C_{1-4} alkyl, C_{1-3}

Sawai Ex 1003 Page 8 of 175 alkoxy, fluoro, chloro, bromo or trifluoromethyl), phenyl- $(CH_2)_m$ - (wherein m is 1, 2 or 3), $-(CH_2)_nCH(CH_3)$ -phenyl or phenyl- $(CH_2)_nCH(CH_3)$ - (wherein n is 0, 1 or 2).

- 4 -

Various substituents in the formula I will be described in detail with reference to specific examples. However, it should be understood that the present invention is by no means restricted by such specific examples.

10

5

 C_{1-6} alkyl for R^1 , R^2 , R^3 , R^4 , R^6 and R^9 includes, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and t-butyl. C_{1-3} alkoxy for R^1 , R^2 , R^3 , R^4 and R^6 includes, for example, methoxy, ethoxy, n-propoxy and i-propoxy.

15

1

 C_{1-3} alkyl for R^{11} includes, for example, methyl, ethyl, n-propyl and i-propyl.

 C_{1-3} alkyl for R^{13} includes, for example, methyl, ethyl, n-propyl and i-propyl.

Alkyl for R¹⁴ includes, for example, methyl, ethyl, 20 n-propyl, i-propyl, n-butyl and i-butyl.

M is a metal capable of forming a pharmaceutically acceptable salt, and it includes, for example, sodium and potassium.

CO2^M includes, for example, -CO2^{NH}4 and -CO2^H.
25 (primary to tertiary lower alkylamine such as trimethylamine).

 C_{1-6} alkyl for R⁵ includes, for example, methyl,

ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

- 5 -

C₃₋₆ cycloalkyl for R⁵ includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

 C_{2-3} alkenyl for R^5 includes, for example, vinyl and i-propenyl.

Phenyl-(CH₂)_m- for R^5 includes, for example, benzyl, β -phenylethyl and γ -phenylpropyl.

Phenyl-(CH₂)_nCH(CH₃)- for R⁵ includes, for example, 10 α -phenylethyl and α -benzylethyl.

 $\rm C_{1-3}$ alkyl for $\rm R^7$ and $\rm R^8$ includes, for example, methyl, ethyl, n-propyl and i-propyl.

Further, these compounds may have at least one or two asymmetric carbon atoms and may have at least two to four 15 optical isomers. The compounds of the formula I include all of these optical isomers and all of the mixtures

thereof.

1

Trt.

5

Among compounds having carboxylic acid moieties falling outside the definition of $-CO_2R^{12}$ of the

20 carboxylic acid moiety of substituent Z of the compounds of the present invention, those which undergo physiclogical hydrolysis, after intake, to produce the corresponding carboxylic acids (compounds wherein the -CO₂R¹² moiety is -CO₂H) are equivalent to the compounds

25 of the present invention.

Now, preferred substituents of the compounds of the present invention will be described.

In the following preferred, more preferred still further perferred and most preferred examples, the numerals for the positions of the substituents indicate the positions on the quinoline ring. For example, N' shown by e.g. 1' or 2' indicates the position of the substituent on the phenyl substituted at the 4-position of the quinoline ring (the carbon connected to the quinoline ring is designated as 1'). The meanings of the respective substituents are the same as the above-mentioned meanings.

- 6 -

Preferred substituents for R^1 , R^2 and R^6 are hydrogen, fluoro, chloro, bromo, C_{1-3} alkyl, C_{1-3} alkoxy, C_{3-6} cycloalkyl, dimethylamino, hydroxy, hydroxymethyl, hydroxyethyl, trifluoromethyl, trifluoromethoxy, difluoromethoxy, phenoxy and benzyloxy.

Further, when R^6 is hydrogen, it is preferred that R^1 and R^2 together form methylenedioxy.

As preferred examples for R^3 and R^4 , when R^4 is hydrogen, R^3 is hydrogen, 3'-fluoro, 3'-chloro, 3'-methyl, 4'-methyl, 4'-chloro and 4'-fluoro.

20

I

15

Sec. Colo

5

10

Other preferred combinations of R³ and R⁴ include 3'-methyl-4'-chloro, 3',5'-dichloro, 3',5'-difluoro,


3',5'-dimethyl and 3'-methyl-4'-fluoro.

Preferred examples for R^5 include primary and secondary C_{1-6} alkyl and C_{3-6} cycloalkyl.

25

Preferred examples for Y include $-CH_2-CH_2$ and -CH=CH-.

Preferred examples for Z include



 $-CH(OH)CH_2CH_2(OH)CH_2CO_2R^{12}$, $-CH(OH)CH_2C(O)CH_2CO_2R^{12}$ and -CH(OH)CH2C(OR¹³)2CH2CO2R¹².

Now, more preferred substituents of the compounds of the present invention will be described.

10

5

As more preferred examples for R^1 , R^2 and R^6 , when both R^2 and R^6 are hydrogen, R^1 is hydrogen, 5-fluoro, 6-fluoro, 7-fluoro, 8-fluoro, 5-chloro, 6-chloro, 7-chloro, 8-chloro, 5-bromo, 6-bromo, 7-bromo, 8-bromo, 5-methyl, 6-methyl, 7-methyl, 8-methyl, 5-methoxy,

- 15 6-methoxy, 7-methoxy, 8-methoxy, 5-trifluoromethyl, 6-trifluoromethyl, 7-trifluoromethyl, 8-trifluoromethyl, 6-trifluoromethoxy, 6-difluoromethoxy, 8-hydroxyethyl, 5-hydroxy, 6-hydroxy, 7-hydroxy, 8-hydroxy, 6-ethyl, 6-n-butyl and 7-dimethylamino.
- 20

1

When R^6 is hydrogen, R^1 and R^2 together represent 6-chloro-8-methyl, 6-bromo-7-methoxy, 6-methyl-7-chloro, 6-chloro-8-hydroxy, 5-methyl-2-hydroxy, 6-methoxy-7-chloro, 6-chloro-7-methoxy, 6-hydroxy-7-chloro, 6-chloro-7-hydroxy, 6-chloro-8-bromo,

5-chloro-6-hydroxy, 6-bromo-8-chloro, 6-bromo-8-hydroxy, 25 5-methyl-8-chloro, 7-hydroxy-8-chloro, 6-bromo-8-hydroxy, 6-methoxy-7-methyl, 6-chloro-8-bromo, 6-methyl-8-bromo,

6,7-difluoro, 6,8-difluoro, 6,7-methylenedioxy, 6,8-dichloro, 5,8-dimethyl, 6,8-dimethyl, 6,7-dimethoxy, 6,7-diethoxy, 6,7-dibromo or 6,8-dibromo.

- 8 -

5

1

When R^1 , R^2 and R^6 are not hydrogen, they together represent 5,7-dimethoxy-8-hydroxy, 5,8-dichloro-6-hydroxy, 6,7,8-trimethoxy, 6,7,8-trimethyl, 6,7,8-trichloro,

5-fluoro-6,8-dibromo or 5-chloro-6,8-dibromo.

As more preferred examples for R^3 and R^4 , when R^3 is hydrogen, R^4 is hydrogen, 4'-methyl, 4'-chloro or

10 4'-fluoro. When both R³ and R⁴ are not hydrogen, they together represent 3',5'-dimethyl or 3'-methyl-4'-fluoro. As more preferred examples for R⁵, the above-mentioned preferred examples of R⁵ may be mentioned.

As preferred examples for Y, -CH₂-CH₂- and (E)--CH=CH-15 may be mentioned. As more preferred examples for Z, the above preferred examples for Z may be mentioned.

Now, still further preferred substituents of the compounds of the present invention will be described. As examples for R^1 , R^2 and R^6 , when both R^2 and R^6 are

20 hydrogen, R¹ is hydrogen, 6-methyl, 6-ethyl, 6-trifluoromethyl, 6-hydroxy, 6-methoxy, 6-chloro, 6-bromo, 6-n-butyl and 7-dimethylamino.

. When only R^6 is hydrogen, R^1 and R^2 represent

6,8-dichloro, 5,8-dimethyl, 6,8-dimethyl, 6,7-dimethoxy,
6,7-diethoxy, 6,7-dibromo, 6,8-dibromo, 6,7-difluoro and
6,8-difluoro.

As still further preferred examples for R^3 and R^4 ,

when R^3 is hydrogen, R^4 is hydrogen, 4'-chloro or 4'-fluoro, or R^3 and R^4 together represent 3'-methyl-4'-fluoro.

Still further preferred examples for R⁵ include ethyl, 5 n-propyl, i-propyl and cyclopropyl.

- 9 -

Still further preferred examples for Y include (E)--CH=CH-.

As still further preferred examples for Z, the above-mentioned preferred example for Z may be mentioned.

10

1

Now, the most preferred substituents for the compounds of the present invention will be described.

As the most preferred examples for R^1 , R^2 and R^6 , when both R^2 and R^6 are hydrogen, R^1 is hydrogen, 6-methyl or 6-chloro.

15 When only R⁶ is hydrogen, R¹ and R² together represent, for example, 6,7-dimethoxy.

As the most preferred examples for R^3 and R^4 , R^3 is hydrogen and R^4 is hydrogen, 4'-chloro or 4'-fluoro.

The most preferred examples for R⁵ include i-propyl 20 and cyclopropyl. The most preferred example for Y may be (E)--CH=CH-.

As the most preferred examples for Z, the above-mentioned preferred examples for Z may be mentioned.

Now, particularly preferred specific compounds of the 25 present invention will be presented. The following compounds (a) to (z) are shown in the form of carboxylic acids. However, the present invention include not only the compounds in the form of carboxylic acids but also the corresponding lactones formed by the condensation of the carboxylic acids with hydroxy at the 5-position, and sodium salts and lower alkyl esters (such as methyl, ethyl, i-propyl and n-propyl esters) of the carboxylic

- 10 -

acids, which can be physiologically hydrolyzed to the carboxylic acids.

(a) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-quinolin-3'-yl]-hept-6-enoic acid

10

5

(b) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid

(c) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-6'-methyl-quinolin-3'-yl]-hept-6-enoic 15 acid

(d) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-6',7'-dimethoxy-quinolin-3'-yl]-hept-6enoic acid

(e) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-20 cyclopropyl-quinolin-3'-yl]-hept-6-enoic acid

(f) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'cyclopropyl-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid (g) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'cyclopropyl-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid

25

.

1

(h) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'cyclopropyl-6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid (i) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(l''-methylethyl)-quinolin-3'-yl]-hept-6-enoic acid (j) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(l''-methylethyl)-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid

- 11 -

(k) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(l''-methylethyl)-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid

(1) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-10 (l''-methylethyl)-6',7'-dimethoxy-quinolin-3'-yl]-hept-6enoic acid

(m) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'cyclopropyl-quinolin-3'-yl]-hept-6-enoic acid

(n) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'15 cyclopropyl-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid
(o) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'cyclopropyl-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid
(p) (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-

cyclopropyl-6'7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic 20 acid

(q) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(l''methylethyl)-quinolin-3'-yl]-hept-6-enoic acid

(r) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-

methylethyl)-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid

25

I

5

(s) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-

methylethyl)-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid
 (t) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-

methylethyl)-6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid

- 12 -

(u) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropylquinolin-3'-yl]-hept-6-enoic acid

1.

5

15

I

:

(v) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-6'chloro-quinolin-3'-yl]-hept-6-enoic acid


(w) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-6'methyl-quinolin-3'-yl]-hept-6-enoic acid


(x) (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl 6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid


(y) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-6'-methoxy-quinolin-3'-yl]-hept-6-enoic acid

(z) (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-

cyclopropyl-6'-methoxy-quinolin-3'-yl]-hept-6-enoic acid The mevalonolactones of the formula I can be prepared by the following reaction scheme. The enal III can also be prepared by processes K, L and M.








, tr


.....

I

, es

(






16

141

:

....





In the above reaction scheme, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 and R^{12} are as defined above with respect to the formula I, and R^{21} and R^{22} independently represent C_{1-4} lower alkyl such as methyl, ethyl, n-propyl, i-propyl or n-butyl.

- 18 -

Step A represents a reduction reaction of the ester to a primary alcohol. Such reduction reaction can be conducted by using various metal hydrides, preferably diisobutylaluminium hydride, in a solvent such as

10 tetrahydrofuran or toluene at a temperature of from -20 to 20° C, preferably from -10 to 10° C.

Step B represents an oxidation reaction of the primary alcohol to an aldehyde, which can be conducted by using various oxidizing agents. Preferably, the reaction can be conducted by using pyridinium chlorochromate in methylene chloride at a temperature of from 0 to 25°C, or by using oxalyl chloride, dimethyl sulfoxide and a tertiary amine such as triethylamine (Swern oxidation), or by using a sulfur trioxide pyridine complex.

20

Ĩ

5

.

Step C represents a synthesis of a

3-ethoxy-l-hydroxy-2-propene derivative, which can be prepared by reacting a compound V to lithium compound which has been preliminarily formed by treating cis-l-ethoxy-2-(tri-n-butylstannyl)ethylene with butyl lithium in tetrahydrofuran.

As the reaction temperature, it is preferred to employ a low temperature at a level of from -60 to -78° C.

Step D represents a synthesis of an enal by acidic hydrolysis. As the acid catalyst, it is preferred to employ p-toluene sulfonic acid, hydrochloric acid or sulfuric acid, and the reaction may be conducted in a

- 19 -

sto sta

.

-

I

20

- 5 solvent mixture of water and tetrahydrofuran or ethanol at a temperature of from 10 to 25°C. The 3-ethoxy-l-hydroxy-2-propene derivative obtained in Step C can be used in Step D without purification i.e. by simply removing tetra-n-butyl tin formed simultaneously.
- Step E represents a double anion condensation reaction between the enal III and an acetoacetate. Such condensation reaction is preferably conducted by using sodium hydride and n-butyl lithium as the base in tetrahydrofuran at a temperature of from -80 to 0°C, preferably from -30 to -10°C.

Step F represents a reduction reaction of the carbonyl group, which can be conudcted by using a metal hydride, preferably sodium borohydride in ethanol at a temperature of from -10 to 25°C, preferably from -10 to 5°C.

Further, the reduction reaction may be conducted by using zinc borohydride in dry ethyl ether or dry tetrahydrofuran at a temperature of -100 to 25° C, preferably from -80 to -50° C.

Step G is a step for hydrolyzing the ester. The hydrolysis can be conducted by using an equimolar amount of a base, preferably potassium hydroxide or sodium hydroxide, in a solvent mixture of water and methanol or

Sawai Ex 1003 Page 24 of 175

ethanol at a temperature of from 10 to 25° C. The free acid hereby obtained may be converted to a salt with a suitable base.

- 20 -

.*

*

T

Step H is a step for forming a mevalonolactone by the dehydration reaction of the free hydroxy acid I-2. The dehydration reaction can be conducted in benzene or toluene under reflux while removing the resulting water or by adding a suitable dehydrating agent such as molecular sieve.

10 Further, the dehydration reaction may be conducted in dry methylene chloride by using a lactone-forming agent such as carbodiimide, preferably a water soluble carbodiimide such as

N-cyclohexyl-N'-[2'-(methylmorpholinium)ethyl]carbodiimide

15 p-toluene sulfonate at a temperature of from 10 to 35° C, preferably from 20 to 25° C.

Step J represents a reaction for hydrogenating the double bond connecting the mevalonolactone moiety and the quinoline ring. This hydrogenation reaction can be

20 conducted by using a catalytic amount of palladium-carbon or rhodium-carbon in a solvent such as methanol, ethanol, tetrahydrofuran or acetonitrile at a temperature of from 0 to 50°C, preferably from 10 to 25°C.

Step K represents a reaction for the synthesis of an α,β-unsaturated carboxylic acid ester, whereby a trans-form α,β-unsaturated carboxylic acid ester can be obtained by a so-called Horner-Wittig reaction by using an

> Sawai Ex 1003 Page 25 of 175

alkoxycarbonylmethyl phosphonate. The reaction is conducted by using sodium hydride or potassium t-butoxide as the base in dry tetrahydrofuran at a temperature of from -30 to 0° C, preferably from -20 to -15° C.

- 21 -

5

Nº .

5

2

1

Step L represents a reduction reaction of the α , β -unsaturated carboxylic acid ester to an allyl alcohol. This reduction reaction can be conducted by using various metal hydrides, preferably diisobutylaluminiumhydride, in a solvent such as dry tetrahydrofuran or toluene at a 10 temperature of from -10 to 10°C, preferably from -10 to

o°c.

Step M represents an oxidation reaction of the allyl alcohol to an enal. This oxidation reaction can be conducted by using various oxidizing agents, particularly

15 active manganese dioxide, in a solvent such as tetrahydrofuran, acetone, ethyl ether or ethyl acetate at a temperatrue of from 0 to 100°C, preferably from 15 to 50°C.

Step N represents a reaction for the synthesis of an 20 α , β -unsaturated ketone by the selective oxidation of the dihydroxy carboxylic acid ester. This reaction can be conducted by using activated manganese dioxide in a solvent such as ethyl ether, tetrahydrofuran, benzene or toluene at a temperature of from 20 to 80°C, preferably from 40 to 80°C. 25

In addition to the compounds disclosed in Examples given hereinafter, compounds of the formulas I-2 and I-5

1-1

given in Table 1 can be prepared by the process of the present invention. In Table 1, i- means iso, sec- means secondary and c- means cyclo. Likewise, Me means methyl, Et means ethyl, Pr means propyl, Bu means butyl, Pent means pentyl, Hex means hexyl and Ph means phenyl.

5

1

- 22 -

Table 1

4

5

+

I

ore	1					
		R ³	R ⁴	0 H	*	
		R •	$[\mathcal{O}]$	L co	2 R 1 2	
	R	2	X	0 H		
	R	101	OI R ⁵	Į –	$\frac{2}{5} (R^{12} = H)$ $\frac{2}{5} (R^{12} = Na)$	
_			n "n	1 -	• 0 (R••=Na)	
-	R¹	R ²	R ³	R 4	R⁵ R	6
	6 — 0 Me	Н	Н	Н	:_D_ U	
	6 - 0 Me	Н	4 - F	Н	i — Pr H i — Pr H	
	6 - Br	H	4 — F	н	i - Pr H i - Pr H	
	6 — Me	8 — Me	4 — F	Н	i-Pr H	
	7 — 0 Me	8 — O Me	e 4 — F	Н	i-Pr H	
	6 - Br	Н	2 — F	Н	i-Pr H	
22	6,7	ι.		11 (r)		
	$\langle \rangle$	>	4 — F	Н	i-Pr H	
	Н	Н	4 — F	H	- Н	
	H	Н	(\checkmark	
	Н		4 — Ph	H	i-Pr H	
		H	4 — PhCH ₂	H	i-Pr H	
	6-C L	H	4 — F	Н	c-Pr H	
	6-C 2	Н	4 — F	Η	sec-Bu H	
	6 - 0 C H ₂ P h	Н	4 – F	Н	i-Pr H	
	Н	Η	4 — F	H	i-Bu H	
	Н	Н	4 - F	Н	c-Pent H	
	6-C L	Н	4 - F	H	c-Pent H	
6	-MezN	Н	4 – F	Н	i-Pr H	

- 23 -

Sawai Ex 1003 Page 28 of 175

R 1	R ²	R ³	R ⁴	R ^s	R °
6-Me	H	4 — F	Н	c - Pr	H
6-i-Pr	Н	4 — F	Н	i-Pr	Н
7-Me	Н	4 — F	Н	c — Pr	Н
6-0Me	Н	4 - F	Н	c — Pr	Н
6 - B r	Н	4 — F	Н	c — Pr	Н
6-i-Pr	Н	4 — F	Н	c — Pr	Н
6-C 2	8-C L	4 — F	Н	c — Pr	Н
5 - F	6 - B r	4 — F	Н	i-Pr	8-Br
6-0Me	7-0Me	4 — F	Н	i-Pr	8-0Me
6-Me	7-Me	4 – F	Н	i-Pr	8-Me
6-C L	7-C L	4 — F	Н	i-Pr	8-C L
Н	Н	4 — F	Н	c-Bu	Н
Н	Н	4 — F	Н	c-Hex	Н
6-0Me	7-0Me	Н	Н	i-Pr	Н
6-0Me	7-0Me	4-C L	Η	i-Pr	Н
6-0Me	7-0Me	Н	Н	c-Pr	Н
6-0Me	7-0Me	4-C L	H	c-Pr	Н
6-0Me	7-0Me	4 - F	Н	c-Pr	Н

25

ť

I

R '	R ²	R ³	R 4	R ⁵	R °
6-Me	Н	Н	Н	i-Pr	 H
6-Me	Н	4-C L	Н	i-Pr	Н
6-Me	Н	Н	Н	c-Pr	н
6-Me	Н	4-C L	Н	c-Pr	Н
6-Me	Η	4 - F	Н	c-Pr	Н
6-C L	Н	Н	Н	i-Pr	н
6-C L	Н	4-C L	Н	i-Pr	Н
6-C L	Н	Н	Н	c-Pr	H
6-C L	Н	4-C L	Н	c-Pr	Н
6-C L	Н	4 - F	Н	c-Pr	Н
Н	Н	Н	Н	i-Pr	H
Н	Н	4-C L	Н	i-Pr	H
Н	H	H	Н	c-Pr	Н
Н	Η	4-C L	Н	c-Pr	H
Н	H	4 - F	Н	c-Pr	Н

26

I

Further, pharmaceutically acceptable salts such as potassium salts or esters such as ethyl esters or methyl esters of these compounds can be prepared in the same manner.

- 26 -

(

5

20

.,"

Ĩ

The compounds of the present invention exhibit high inhibitory activities against the cholesterol biosynthesis wherein HMG-CoA reductase acts as a rate limiting enzyme, as shown by the test results given hereinafter, and thus are capable of suppressing or reducing the amount of

10 cholesterol in blood as lipoprotein. Thus, the compounds of the present invention are useful as curing agents against hyperlipidemia, hyperlipoproteinemia and atheroscleosis.

They may be formulated into various suitable formulations depending upon the manner of the administration. The compounds of the present invention may be administered in the form of free acids or in the form of physiologically hydrolyzable and acceptable esters or lactones, or pharmaceutically acceptable salts.

The pharmaceutical composition of the present invention is preferably administered orally in the form of the compound of the present invention per se or in the form of powders, granules, tablets or capsules formulated by mixing the compound of the present invention with a

25 suitable pharmaceutically acceptable carrier including a binder such as hydroxypropyl cellulose, syrup, gum arabic, gelatin, sorbitol, tragacanth gum, polyvinyl pyrrolidone

Sawai Ex 1003 Page 31 of 175

or CMC-Ca, an excipient such as lactose, sugar, corn starch, calcium phosphate, sorbitol, glycine or crystal cellulose powder, a lubricant such as magnesium stearate, talk, polyethylene glycol or silica, and a disintegrator such as potato starch.

- 27 -

However, the pharmaceutical composition of the present invention is not limited to such oral administration and it is applicable for parenteral administration. For example, it may be administered in the form of e.g. a

- 10 suppository formulated by using oily base material such as cacao butter, polyethylene glycol, lanolin or fatty acid triglyceride, a transdermal therapeutic base formulated by using liquid paraffin, white vaseline, a higher alcohol, Macrogol ointment, hydrophilic ointment or hydro-gel base
- 15 material, an injection formulation formulated by using one or more materials selected from the group consisting of polyethylene glycol, hydro-gel base material, distilled water, distilled water for injection and excipient such as lactose or corn starch, or a formulation for
- 20 administration through mucous membranes such as an ocular mucous membrane, a nasal mucous membrane and an oral mucous membrane.

1' e - -

5

.

I

Further, the compounds of the present invention may be combined with basic ion-exchange resins which are capable 25 of binding bile acids and yet not being absorbed in

gastraintestinal tract.

The daily dose of the compound of the formula I is

from 0.05 to 500 mg, preferably from 0.5 to 50 mg for an adult. It is administered from once to three times per day. The dose may of course be varied depending upon the age, the weight or the condition of illness of the patient.

The compounds of the formulas II to VII are novel, and they are important intermediates for the preparation of the compounds of the formula I. Accordingly, the present invention relates also to the compounds of the formulas II 10 to VII and the processes for their production.

Now, the present invention will be described in further detail with reference to Test Examples for the pharmacological activities of the compounds of the present invention, their Preparation Examples and Formulation

15 Examples. However, it should be understood that the present invention is by no means restricted by such specific Examples.

PHARMACOLOGICAL TEST EXAMPLES

. 15

5

I

Test A: Inhibition of cholesterol biosynthesis from 20 acetate in vitro

Enzyme solution was prepared from liver of male Wistar rat billialy cannulated and discharged bile for over 24 hours. Liver was cut out at mid-dark and microsome and supernatant fraction which was precipitable with 40-80% of

25 saturation of ammonium sulfate (sup fraction) were prepared from liver homogenate according to the modified method of Knauss et. al.; Kuroda, M., et. al., Biochim.

- 28 -

Biophys. Acta, 489, 119 (1977). For assay of cholesterol biosynthesis, microsome (0.1 mg protein) and sup fraction (1.0 mg protein) were incubated for 2 hours at 37° C in 200 µl of the reaction mixture containing ATP; 1 mM,

- 29 -

5 Glutathione; 6 mM, Glucose-l-phosphate; 10 mM, NAD; 0.25 mM, NADP; 0.25 mM, CoA; 0.04 mM and 0.2 mM $[2^{-14}C]$ sodium acetate (0.2 µCi) with 4 µl of test compound solution dissolved in water or dimethyl sulfoxide. To stop reaction and saponify, 1 ml of 15% EtOH-KOH was added to

10 the reactions and heated at 75°C for 1 hour. Nonsaponifiable lipids were extracted with petroleum ether and incorporated ¹⁴C radioactivity was counted. Inhibitory activity of compounds was indicated with IC50. Test B: <u>Inhibition of cholesterol biosynthesis in</u>

15 culture cells

I

Hep G2 cells at over 5th passage were seeded to 12 well plates and incubated with Dulbecco's modified Eagle (DME) medium containing 10% of fetal bovine serum (FBS) at 37° C, 5% CO₂ until cells were confluent for about 7 days.

- 20 Cells were exposed to the DME medium containing 5% of lipoprotein deficient serum (LpDS) prepared by ultracentrifugation method for over 24 hours. Medium was changed to 0.5 ml of fresh 5% LpDS containing DME before assay and 10 µl of test compound solution dissolved in
- 25 water or DMSO were added. 0.2 μ Ci of $[2-^{14}C]$ sodium acetate (20 μ l) was added at O hr(B-1) or 4 hrs(B-2) after addition of compounds. After 4 hrs further incubation with $[2-^{14}C]$ sodium acetate, medium was removed and cells

were washed with phosphate buffered saline(PBS) chilled at 4° C. Cells were scraped with rubber policeman and collected to tubes with PBS and digested with 0.2 ml of 0.5 N KOH at 37° C. Aliquot of digestion was used for

- 30 -

- 5 protein analysis and remaining was saponified with 1 ml of 15% EtOH-KOH at 75°C for 1 hour. Nonsaponifiable lipids were extracted with petroleum ether and ¹⁴C radioactivity was counted. Counts were revised by cell protein and indicated with DPM/mg protein. Inhibitory activity of 10 compounds was indicated with IC50.
 - Test C: Inhibition of cholesterol biosynthesis in vivo Male Sprague-Dawley rats weighing about 150 g were fed normal Purina chow diet and water ad libitum, and exposed to 12 hours light/12 hours dark lighting pattern (2:00 PM
- 15 2:00 AM dark) prior to use for in vivo inhibition test of cholesterol biosynthesis. Animals were separated groups consisting of five rats as to be average mean body weight in each groups. Test compounds at dosage of 0.02-0.2 mg/kg body weight (0.4 ml/l00 g body weight),
- 20 were dissolved in water or suspended or in 0.5% methyl cellulose and orally administered at 2-3 hours before mid-dark (8:00 PM), while cholesterol biosynthesis reaches to maximum in rats. As control, rats were orally administered only water or vehicle. At 90 minutes after
- 25 sample administration, rats were injected intraperitoneally with 10 μ Ci of $[2^{-14}C]$ sodium acetate at volume of 0.2 ml per one. 2 Hours later, blood samples

were obtained and serum were separated immediately. Total lipids were extracted according to the method of Folch et al. and saponified with EtOH-KOH. Nonsaponifiable lipids were extracted with petroleum ether and radio activity incorporated into nonsaponifiable lipids was counted.

- 31 -

Inhibitory activity was indicated as percent decrease of counts in testing groups (DPM/2 ml serum/2 hours) from that in control group.

With respect to the compounds of the present 10 invention, the inhibitory activities against the cholesterol biosynthesis in which HMG-CoA reductase serves as a rate limiting enzyme, were measured by the above Test A and B. The results are shown in Tables, 2, 2-2, 3 and 3-2. Further, the results of the measurements by Test C

an 1979 of the and 1986 Name of any second proceedings

15 are also presented.

5

1

5 2 \ \	/ _	Compound	I ₅₀ (molar concentration)
1	0	(Compounds of the present invention)	
		I-13	1.25×10^{-7}
1	5	I-51	1.0×10^{-8}
I	5	I-52	7.1 x 10 ⁻⁸
		I-53	1.9×10^{-7}
2	0	(Reference compounds)	
		Mevinolin	1.4×10^{-8}
25	5	CS-514	1.4 x 10^{-8} 9.0 x 10^{-9}

- 32 -

Table 2: Inhibitory activities by Test A

In Table 2-2, the relative activities are shown based on the activities of CS-514 being evaluated to be 1.

30

I

÷...

.

. . .

Table 2-2: Relative activities by Test A

Compound	Relative activities
(Comounds of the present invention)	a
1-16	1.75
I-116	2.25
I-117	0.37
I-120	3.21
I-522	0.76

- 33 -

Structures of reference compounds:


(l) Mevinolin

. .


2

F 1.3

I



(2) CS-514



- 34 -

Table 3: Inhibitory activities by Test B-1

5	Comp	Compound			(molar	concentration)
VIV	of t	pound he present ention)	51. 51.	2		
1-1		-51		l	x \10 ⁻	7
1		erence ound)				
	C	S-514		3.5	x 10 ⁻⁷	7
• 2	0 In	Table 3-2	the rol	lativo act	initio	are shown has

In Table 3-2, the relative activities are shown based on the activities of CS-514 being evaluated to be 1.

25

30

35

I

. .

-

2

. 4 .

Table 3-2: Relative activities by Test B-1

Compound	Relative activities
I-116	19.4
I-520	20.0
II-20	20.8

Results of the measurement of the inhibitory

- activities by Test C
- 40

The percent decrease of counts after the oral administration of 0.05 mg/kg of compound I-520 was 55% relative to the measured value of the control group. The percent decrease of counts after the oral administration of 10 mg/kg of CS-514 was 55% under the same condition.

45 The compounds of the present invention exhibited

activities superior to the reference compound such as CS-514 or Mevinolin in Test A, and exhibited activities superior to CS-514 in Tests B and C. Test D: Acute toxicity

- 35 -

· ` .

2

I

....

5

A 0.5% CMC suspension of a test compound was orally administered to ICR male mice (group of three mice). The acute toxicity was determined based on the mortality after seven days. With compound I-57, I-58, I-59, I-511, I-512, I-513, I-514, I-515, I-517 and I-523 of the present

10 invention, the mortality was 0% even when they were orally administered in an amount of 1000 mg/kg. EXAMPLE 1

Ethyl (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-quinolin-3'-yl]-hept-6-enoate (compound

EXAMPLE 1-a: Ethyl 4-(4'-fluorophenyl)-2-(1'methylethyl)-quinolin-3-yl-carboxylate (compound VII-1)

The synthesis was conducted in accordance with the 20 method disclosed in J. Org. Chem., 2899 (1966).

6.45 g (0.03 mol) of 2-amino-4'-fluorobenzophenone, 5.53 g (0.035 mol) of ethyl isobutyrylacetate and 0.1 ml of conc. sulfuric acid were dissolved in 30 ml of glacial acetic acid, and the mixture was heated at 100°C for about

25 10 hours. After confirming the substantial disappearance of 2-amino-4'-fluorobenzophenone by thin layer chromatography, the reaction solution was cooled to room

temperature, and a mixture of 45 ml of conc. aqueous ammonia and 120 ml of water cooled with ice, was gradually added thereto. A separated oily substance was solidified when left to stand overnight in a refrigerator. This

- 36 -

.

.....

Ĩ

5 solid was recrystallized from a small amount of ethanol to obtain 6.47 g (55%) of white powder. Melting point: 68-70.5°C
EXAMPLE 1 by 4 (4) 51

EXAMPLE 1-b: <u>4-(4'-fluorophenyl)-3-hydroxymethyl-2-(1'-</u> methylethyl)-quinoline (compound VI-1)

- 10 5.4 g (0.016 mol) of compound VII-l was dissolved in dry toluene under a nitrogen atmosphere and cooled in ice bath to 0°C. To this solution, 40 ml of a 16 wt% diisobutylaluminium hydride-toluene solution was dropwise added, and the mixture was stirred at 0°C for two hours.
- 15 After confirming the complete disappearance of compound VII-1 by thin layer chromatography, a saturated ammonium chloride solution was added thereto at 0°C to terminate the reaction. Ethyl ether was added to the reaction mixture, and the organic layer was separated. A gelled product was
- 20 dissolved by an addition of an aqueous sodium hydroxide solution and extracted anew with ethyl ether. The ethyl ether extracts were put together, dried over anhydrous magnesium sulfate and filtered. The solvent was distilled off. The residual oil underwent crystallization when left

25 to stand. It was recrystallized from ethyl acetate-n-hexane to obtain 3.3 g of white crystals. Yield: 70%. Melting point: 136-137^oC. EXAMPLE 1-c: <u>4-(4'-fluorophenyl)-2-(1'-methylethyl)-</u> <u>quinolin-3-yl-carboxyaldehyde (compound V-1)</u>

.

:

2.0 g (9.3 mmol) of pyridinium chlorochromate and 0.4 g of anhydrous sodium acetate was suspended in 10 ml of

37 -

- 5 dry dichloromethane. To this suspension, a solution obtained by dissolving 1 g (3.4 mmol) of compound VI-1 in 10 ml of dry dichloromethane, was immediately added at room temerature. The mixture was stirred for one hour. Then, 100 ml of ethyl ether was added thereto, and the
- 10 mixture was throughly mixed. The reaction mixture was filtered under suction through a silica gel layer. The filtrate was dried under reduced pressure. The residue was dissolved in the isopropyl ether, and insoluble substances were filtered off. The filtrate was again
- 15 dried under reduced pressure, and the residue was recrystallized from diisopropyl ether to obtain 0.7 g (Yield: 70%) of slightly yellow prism crystals. Melting point: 124-126°C.

EXAMPLE 1-d: 3-(3'-ethoxy-1'-hydroxy-2'-propeny1)-4-(4'-

- 20 <u>fluorophenyl)-2-(l'-methylethyl)-quinoline (compound IV-1)</u> l.13 g (3.13 mmol) of cis-l-ethoxy-2-(tri-nbutylstannyl)ethylene was dissolved in 8 ml of dry tetrahydrofuran, and the solution was cooled to -78°C in a nitrogen stream. To this solution, 2 ml (3.2 mmol) of a
- 25 15 wt% n-butyllithium-n-hexane solution was dropwise added. The mixture was stirred for 45 minutes. Then, a solution prepared by dissolving 0.76 g (2.6 mmol) of

compound V-1 in 10 ml of dry tetrahydrofuran was dropwise added thereto. The reaction mixture was stirred at -78° C for two hours. Then, 2 ml of a saturated ammonium chloride solution was added thereto to terminate the

- 38 -

- 5 reaction. The organic layer was extracted with diethyl ether, and the diethyl ether extract was washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure. The residue was separated
- 10 with n-hexane and acetonitrile. The solvent was distilled off under reduced pressure from the acetonitrile layer, and an oily substance thereby obtained was purified by silica gel column chromatography (eluent: 2.5% methanol-chloroform) to obtain 0.91 g of the desired
- 15 compound in a purified oily form. H-MNR (CDCl₃) ₆ ppm:

.

.

I

1.l(t,3H,7Hz) 1.37(d,6H,J=7Hz) 3.7(m,1H)
3.7(q,2H,J=7Hz) 4.75(t,1H,7Hz) 5.7(m,1H)
5.95(m,1H) 7.05-8.2(m,8H)

20 EXAMPLE 1-e: (E)-3-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-quinolin-3'-yl]propenaldehyde (compound III-1)

0.91 g of compound IV-1 was dissolved in 20 ml of tetrahydrofuran, and 5 ml of water and 100 mg of

25 p-toluenesulfonic acid were added thereto. The mixture was stirred at room temperature for 24 hours. The reaction solution was extracted with diethyl ether a few times. The extracts were washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off. The residue was purified by silica gel column

- 39 -

*

T

5 chromatography (eluent: chloroform) to obtain the desired product as white prism crystals. 0.4 g (50%). Melting point: 127-128°C.

EXAMPLE 1-f: Ethyl (E)-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-quinolin-3'-yl]-5-hydroxy-3-oxohepto-6-10 enoate (compound II-1)

50 mg of 60% sodium hydride was washed with dry petroleum ether and dried under a nitrogen stream, and then suspended in 5 ml of dry tetrahydrofuran. The suspension was cooled to -15° C in a nitrogen atmosphere.

- 15 Then, 120 mg (0.92 mmol) of ethyl acetoacetate was dropwise added thereto, and the mixture was stirred for 15 minutes. Then, 0.6 ml (0.92 mmol) of a 15 wt% n-butyllithium-n-hexane solution was dropwise added thereto, and the mixture was stirred for 30 minutes.
- 20 Then, a solution prepared by dissolving 160 mg (0.5 mmol) of compound III-1 in dry tetrahydrofuran, was dropwise added thereto, and the mixture was stirred for one hour. To the reaction mixture, 1 ml of a saturated ammonium chloride aqueous solution was added at -15°C. Then, the
- 25 mixture was extracted three times with diethyl ether. The diethyl ether solution was washed with a saturated sodium chloride aqueous solution and dried over anhydrous

magnesium sulfate. The solution was evaporated to dryness under reduced pressure. The residue was recrystallized from diisopropyl ether to obtain 130 mg (yield: 59%) of white crystals. Melting point: 99-101°C.

- 40 -

EXAMPLE 1-g: Ethyl (E)-3,5-dihydroxy-7-[4'-(4''fluorophenyl)-2'-(1''-methylethyl)-quinolin-3'-yl]-hept-6-enoate (compound I-11)

110 mg (0.245 mmol) of compound II-1 was dissolved in 5 ml of ethanol in a nitrogen atmosphere, and the solution

- 10 was cooled 0°C. Then, 10 mg (0.263 mmol) of sodium borohydride was added, and the mixturer was stirred for one hour. Then, 1 ml of a 10% hydrochloric acid aqueous solution was added thereto, and the mixture was extracted three times with ethyl ether. The ethyl ether solution
- 15 was washed with a saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. Then, the solution was evaporated to dryness under reduced pressure. The residual oil was purified by silica gel column chromatography (eluent: 5% methanol-chloroform) to

H-NMR (CDCl₃) δ ppm:

1.30(t,3H,J=8Hz) 1.39(d,6H,J=8Hz) 1.4-1.8(m,2H) 2.42(d,2H,J=7Hz) 3.0-3.8 (m,2H) 3.50(m,1H) 3.9-4.6(m,2H) 4.20(q,2H,J=8Hz) 5.35(m,1H) 6.59(m,1H) 7.10-8.18(m,8H)

25

I

-

5

EXAMPLE 2

Sodium salt of (E)-3,5-dihydroxy-7-[4'-(4''fluorophenyl)-2'-(l''-methylethyl)-quinolin-3'-yl]-hept-6-enoic acid (compound I-51)

- 41 -

5

15

1

60 mg (0.133 mmol) of compound I-11 was dissolved in 3 ml of ethanol. Then, 0.26 ml of a 0.5 N sodium hydroxide aqueous solution was dropwise added thereto. The mixture was stirred at room temperature for further one hour, and ethanol was distilled off under reduced pressure. Then, 5 10 ml of water was added thereto, and the mixture was extracted with ethyl ether. The aqueous layer was

freeze-dried to obtain 40 mg (67%) of hygroscopic white powder. Melting point: 207-209°C (decomposed). EXAMPLE 3

(E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-quinolin-3'-yl]-hept-6-enoic acid (compound I-21)

110 mg (0.244 mmol) of compound I-11 was dissolved in 10 ml of ethanol. Then, 0.79 ml of a 0.5 N sodium 20 hydroxide aqueous solution was dropwise added thereto. The mixture was stirred at room temperature for further one hour, and ethanol was distilled off under reduced pressure. Then, 10 ml of water was added thereto, and the mixture was extracted with ethyl ether. The aqueous layer 25 was weakly acidified (pH 4) with a dilute hydrochloric

aqueous solution and extracted three times with ethyl ether. The ethyl ether layers were put together and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off under reduced pressure to obtain 90 mg of slightly yellow oily substance. H-NMR (CDCl₃) & ppm:

- 42 -

5

15

1

1.36(d,6H,J=7Hz) 2.4(m,2H) 3.5(m,1H) 3.45(m,1H) 3.8-4.6(m,2H) 5.40(dd,1H,J₁=19Hz,J₂=8Hz)

6.55 (d,lH,J=19Hz) 7.0-8.3(m,8H)

EXAMPLE 4

(E)-6-[4'-(4''-fluorophenyl)-2'-(1''-methylethyl)-10 guinolin-3'-ylethenyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one (compound I-31)

90 mg of compound I-21 was dissolved in 10 ml of dry toluene, and the solution was refluxed under heating for 3 hours by means of a Dean Stark apparatus.

Toluene was distilled off under reduced pressure, and the residual solid was recrystallized from diisopropyl ether to obtain 40 mg of colorless prism crystals. Melting point: 182-184[°]C.

By silica gel thin chromatography, the product gave 20 two absorption spots close to each other attributable to the diastereomers. (Developping solvent: 3% methanol-chloroform)

These diasteromers were separated and isolated by silica gel thin layer chromatography. [Developping 25 solvent: t-BuOMe/hexane/acetone=7/2/1 (v/v), Rf=0.6 and 0.7 (obtained weight ratio: 1/2)]

Rf=0.7: trans lactone

H-NMR (CDCl₃) δ ppm:

1.40(d,6H,J=7Hz) 1.6(m,2H) 2.65(m,2H) 3.48(m,1H) 4.20(m,1H) 5.15(m,1H) 5.37(dd,1H,J₁=18Hz,J₂=7Hz) 6.68(d,1H,J=19Hz) 7.1-8.2(m,8H)

43 -

Rf=0.6: cis lactone

H-NMR (CDCl₃) δ ppm:

1.40(d,6H,J=7Hz) 1.6(m,2H) 2.65(m,2H) 3.48(m,1H) 4.20(m,1H) 4.65(m,1H) 5.40(dd,1H,J₁=18Hz,J₂=7Hz) 6.66(m,1H) 7.0-8.2(m,8H)

EXAMPLE 5

<u>6-[4'-(4''-fluorophenyl)-2'-(l''-methylethyl)-</u> <u>quinolin-3'-ylethynyl]-4-hydroxy-3,4,5,6-tetrahydro-2H-</u> <u>pyran-2-one (compound I-41)</u>

15

1

10

5

20 mg of a mixture of diastereomers of compound I-31 was dissolved in 5 ml of ethanol, and 10 mg of 5% palladium-carbon was added thereto. The mixture was stirred under a hydrogen atmosphere. After confirming the disappearance of the starting substance and the appearance

20 of a new spot by thin layer chromatography, the palladium-carbon was filtered off, and ethanol was distilled off to obtain colorless oil.

This oil was purified by preparative thin layer chromatography to obtain 16 mg of the desired product as 25 pure colorless oil.

MS(m/e): 408(M⁺+H), 407(M⁺), 366, 292, 278

In the same manner as in Example 1-a, compounds VII-2

to VII-27 were prepared. The physical properties of these compounds are shown in Table 4. (In the Table, R^1 , R^2 , R^3 , R^4 , R^5 and R^{21} correspond to the substituents of compound VII.)

- 44 -

5

2

I

$VII - 4$ HHHHH $i - Pr C_2 H_5$ $85 \cdot 85 \cdot 5$ $VII - 5$ $6 - C \ell$ HHH C_{H_3} $C_{2}H_5$ $100 \cdot 5 \cdot 5 - 101 \cdot 101 \cdot$	Compa	undgı	R ²	R ³	R 4	R ⁵	R ² 1	m.p. (°C)
VII-3 H H H H H H H 102-102. VII-4 H H H H I-Pr C2H5 85.5 VII-5 6-C2 H H H CH3 C2H5 100.5-101. VII-6 6-C2 H H H I-Pr C2H5 105.5-101. VII-7 H H 2-F H i-Pr C2H5 101.0-102. VII-8 7-Me H H 2-F H i-Pr C2H5 101.0-102. VII-9 H 4-C2 H i-Pr C2H5 104.0-102. VII-10 H 4-OMe H i-Pr C2H5 104.0-102. VII-11 H 4-Me H i-Pr C2H5 108.5-109. VII-12 6-C2 H 2-C2 H i-Pr C2H5 101.0 VII-11 H 4-Me H i-Pr C2H5 101.0 109.5 VII-12 6-C2 H 2-C2 H i-Pr </td <td>VII - 2</td> <td>Н</td> <td>H</td> <td>4 - F</td> <td>Н</td> <td>СНз</td> <td>C 2 / 5</td> <td></td>	VII - 2	Н	H	4 - F	Н	СНз	C 2 / 5	
$VII - 4$ HHHHH $i - Pr$ C_{2H_5} 85.5 $VII - 5$ $6 - C \mathcal{L}$ HHH C_{H_3} C_{2H_5} 100.5 $VII - 6$ $6 - C \mathcal{L}$ HHH $i - Pr$ C_{2H_5} $105.5 - 106.5$ $VII - 7$ HH $2 - F$ H $i - Pr$ C_{2H_5} $101.0 - 102.5$ $VII - 7$ HH $2 - F$ H $i - Pr$ C_{2H_5} $101.0 - 102.5$ $VII - 7$ HH $2 - F$ H $i - Pr$ C_{2H_5} $0i1$ $VII - 9$ HH $4 - C \mathcal{L}$ H $i - Pr$ C_{2H_5} $0i1$ $VII - 9$ HH $4 - C \mathcal{L}$ H $i - Pr$ C_{2H_5} $0i1$ $VII - 10$ HH $4 - OMe$ H $i - Pr$ C_{2H_5} $108.5 - 109.5$ $VII - 10$ HH $4 - Me$ H $i - Pr$ C_{2H_5} $101.0 - 103.6$ $VII - 11$ HH $4 - Me$ H $i - Pr$ C_{2H_5} $101.0 - 103.6$ $VII - 12$ $6 - C \mathcal{L}$ H $2 - C \mathcal{L}$ H $i - Pr$ C_{2H_5} $101.0 - 103.6$ $VII - 13$ H $4 - C F_3$ H $i - Pr$ C_{2H_5} $101.0 - 103.6$ $VII - 14$ H $3 - Me$ $5 - Me$ $i - Pr$ C_{2H_5} $0i1$ $VII - 15$ H $3 - Me$ $5 - Me$ $i - Pr$ C_{2H_5} $96.0 - 98.0$ $VII - 16$ $6 - OMe$ $7 - OMe$	VII - 3	Н	Н	Н	Н	CH ₃	C2H5	102-
VII-0 0-C/L H H H CH ₃ C ₂ H ₅ 100.5- 101. VII-6 6-C/L H H H i-Pr C ₂ H ₅ 101.0- 102. VII-7 H H 2-F H i-Pr C ₂ H ₅ 101.0- 102. VII-8 7-Me H H 2-F H i-Pr C ₂ H ₅ 101.0- 102. VII-9 H H 4-C/L H i-Pr C ₂ H ₅ 031 VII-9 H H 4-C/L H i-Pr C ₂ H ₅ 134.0- 136.2 VII-10 H H 4-C/L H i-Pr C ₂ H ₅ 108.5- 109.5 VII-11 H 4-Me H i-Pr C ₂ H ₅ 108.5- 109.5 VII-12 6-C/L H 2-C/L H i-Pr C ₂ H ₅ 101.0 -103.0 VII-13 H 4-CF ₃ H i-Pr C ₂ H ₅ 101.0 -103.0 VII-14 H 3-Me 5-Me i-Pr C ₂ H ₅ 011.0 VII-15 H	.VII - 4	H	Н	Н	H	i-Pı	C 2 li 5	
NI = 00 = 0 = 0 = 2HHHI = PrC = H = 105.5 = 106.VII = 7HH2 = FHI = PrC = H = 102.VII = 87 = MeHHHI = PrC = H = 102.VII = 9HH4 = 0 MeHI = PrC = H = 134.0 = 136.3VII = 9HH4 = 0 MeHI = PrC = H = 134.0 = 136.3VII = 10HH4 = 0 MeHI = PrC = H = 136.3VII = 11HH4 = 0 MeHI = PrC = H = 136.3VII = 126 = 0.6 \mathcal{L} H2 = 0.2 \mathcal{L} HI = PrC = H = 136.3VII = 13HH4 = 0.6 \mathcal{L} HI = PrC = H = 136.3VII = 13HH4 = 0.6 \mathcal{L} HI = PrC = H = 136.3VII = 14H3 = Me5 = MeI = PrC = H = 136.3VII = 15H3 = Me5 = MeI = PrC = H = 136.0VII = 166 = 0 Me7 = 0 Me4 = FHI = PrC = H = 139.0VII = 17H4 = FHn = PrC = H = 139.0VII = 18H4 = FHn = PrC = H = 139.0VII = 18H4 = FHn = PrC = H = 94.5 = 94.5 = 95.5VII = 18H4 = FHI = PrC = H = 94.5 = 95.5VII = 196 = C \mathcal{L} H4 = OPhHI = PrC = H = 94.5 = 95.5VII = 18H	VI - 5	6-C L	Н	Н	Н	СНз	C ₂ H ₅	100.5-
VII-7 n H $2-F$ H i-Pr C_2H_5 101.0-102. VII-8 7-Me H H i-Pr C_2H_5 0il VII-9 H 4-C \mathcal{L} H i-Pr C_2H_5 134.0-136.3 VII-10 H 4-OMe H i-Pr C_2H_5 134.0-136.3 VII-10 H 4-OMe H i-Pr C_2H_5 134.0-136.3 VII-10 H 4-OMe H i-Pr C_2H_5 136.3 VII-11 H 4-Me H i-Pr C_2H_5 108.5-109.5 VII-12 6-C \mathcal{L} H 2-C \mathcal{L} H i-Pr C_2H_5 101.0 VII-12 6-C \mathcal{L} H 2-C \mathcal{L} H i-Pr C_2H_5 101.0 VII-12 6-C \mathcal{L} H 2-C \mathcal{L} H i-Pr C_2H_5 101.0 VII-13 H 4-CF_3 H i-Pr C_2H_5 0il VII-14 H 3-Me 5-Me i-Pr C_2H_5 0il VII-15 H 3-Me 5-Me i-Pr C_2H_5 0il VII-16	VII - 6	6-C L	Н	Н	Н	i-Pr	C ₂ H ₅	101.5 105.5-
VII-8 I-NE H H H I-Pr C2Hs oil VII-9 H H 4-C2 H I-Pr C2Hs 134.0-136.8 VII-10 H H 4-OMe H i-Pr C2Hs 134.0-186.8 VII-10 H H 4-OMe H i-Pr C2Hs 136.8 VII-11 H H 4-OMe H i-Pr C2Hs 108.5 VII-11 H H 4-Me H i-Pr C2Hs 109.5 VII-12 6-C2 H 2-C2 H i-Pr C2Hs 101.0 01.0 -103.0 01 -103.0 01 01 01 VII-13 H 4-CF3 H i-Pr C2Hs 117.5- 119.0 VII-14 H 3-Me 5-Me i-Pr C2Hs oil 01 VII-15 H 3-Me 5-Me i-Pr C2Hs 0il 01 VII-15 H 3-Me 5-Me i-Pr C2Hs 03.0 139.0 139.0 VII-17 H H 4-F	VII - 7	Н	H	2 - F	Н	i-Pr	CzHs	
VII -9 H H $4-C\mathcal{L}$ H $i-Pr$ C_2H_5 $134.0-136.3$ VII -10 H H $4-OMe$ H $i-Pr$ C_2H_5 $88.0-80.5-136.5-109.5$ VII -11 H H $4-Me$ H $i-Pr$ C_2H_5 $108.5-109.5$ VII -12 $6-C\mathcal{L}$ H $2-C\mathcal{L}$ H $i-Pr$ C_2H_5 101.0 -103.0 VII -13 H $4-CF_3$ H $i-Pr$ C_2H_5 $117.5-10.0$ -103.00 VII -13 H $4-CF_3$ H $i-Pr$ C_2H_5 $117.5-10.00$ -103.00 VII -14 H $3-Me$ $4-F$ $i-Pr$ C_2H_5 011.00 -103.00 VII -15 H $3-Me$ $5-Me$ $i-Pr$ C_2H_5 $06.0-98.0$ VII -16 $6-OMe$ $7-OMe$ $4-F$ H $i-Pr$ C_2H_5 $06.0-98.0$ VII -17 H H $4-F$ H $i-Pr$ C_2H_5 $011.33.5-33.0$ VII -18 H H	VII - 8	7-Me	Н	Н	Н	i-Pr	C 2 H 5	
VII-10 H H 4-0Me H i-Pr C ₂ H ₅ 88.0- 89.0 VII-11 H H 4-Me H i-Pr C ₂ H ₅ 108.5- 109.5 VII-12 6-C L H 2-C L H i-Pr C ₂ H ₅ 101.0 -103.0 VII-13 H H 2-C L H i-Pr C ₂ H ₅ 117.5- 119.0 VII-13 H H 2-C L H i-Pr C ₂ H ₅ 117.5- 119.0 VII-14 H H 3-Me 4-F i-Pr C ₂ H ₅ oil VII-14 H 3-Me 4-F i-Pr C ₂ H ₅ oil VII-15 H 3-Me 5-Me i-Pr C ₂ H ₅ oil VII-15 H 3-Me 5-Me i-Pr C ₂ H ₅ oil VII-17 H H 4-F H i-Pr C ₂ H ₅ 96.0- 98.0 VII-17 H H 4-F H n-Pr C ₂ H ₅ 94.5- 95.5 VII-18 H 4-F H i-Pr C ₂ H ₅ 94.5- 95.5 VII-20 H H 4-F H	VI - 9	Н	H	4-C L	H	i-Pr	CzHs	134.0-
VII-11 H 4-Me H $i-\Pr C_2H_5$ 108.5- 109.5 VII-12 6-C H 2-C H $i-\Pr C_2H_5$ 101.0 -103.0 VII-13 H H 2-C H $i-\Pr C_2H_5$ 101.0 -103.0 VII-13 H H 4-CF_3 H $i-\Pr C_2H_5$ 117.5- 119.0 VII-14 H H 3-Me 4-F $i-\Pr C_2H_5$ oil VII-15 H H 3-Me 5-Me $i-\Pr C_2H_5$ oil VII-15 H 3-Me 5-Me $i-\Pr C_2H_5$ oil VII-16 6-OMe 7-OMe 4-F H $i-\Pr C_2H_5$ 96.0- 98.0 VII-17 H H 4-F H $n-\Pr C_2H_5$ 94.5- 95.5 VII-18 H H 4-F H $n-\Pr C_2H_5$ 94.5- 95.5 VII-19 6-C H 4-F H $i-\Pr C_2H_5$ 94.5- 95.5 VII-20 H H 4-F H $i-\Pr C_2H_5$ 94.5- 95.5 II-21 H H <td< td=""><td>VII - 10</td><td>H</td><td>Н</td><td>4-0Me</td><td>H ,</td><td>i-Pr</td><td>CzHs</td><td>88.0-</td></td<>	VII - 10	H	Н	4-0Me	H ,	i-Pr	CzHs	88.0-
VII-12 6-C2 H $2-C2$ H i-Pr C_2H_s 101.0 -103.0 VII-13 H H 4-CF_3 H i-Pr C_2H_s 117.5- VII-13 H H 3-Me 4-F i-Pr C_2H_s 117.5- VII-14 H H 3-Me 4-F i-Pr C_2H_s 0il VII-14 H H 3-Me 5-Me i-Pr C_2H_s 0il VII-15 H H 3-Me 5-Me i-Pr C_2H_s 0il MI-16 6-OMe 7-OMe 4-F H i-Pr C_2H_s 96.0- MI-17 H H 4-F H c_2H_s CH_a 139.0 139.5 MI-18 H H 4-F H n-Pr C_2H_s 94.5- 95.5 II-20 H H 4-F H c-Pr C_13 113.5- II-21 H 4-OPh H i-Pr C_2H_s 96.0- II-22 6-C2	VII - 11	Н	Н	4-Me	Н	i-Pr	C 2 H 5	108.5-
VII-14 H H 3-Me 4-F i-Pr C2Hs 1117.3- 119.0 VII-14 H H 3-Me 4-F i-Pr C2Hs oil VII-15 H H 3-Me 5-Me i-Pr C2Hs oil VII-15 H H 3-Me 5-Me i-Pr C2Hs oil VII-16 6-OMe 7-OMe 4-F H i-Pr C2Hs 96.0- 98.0 VII-17 H H 4-F H c2Hs CH3 139.0 VII-18 H H 4-F H c2Hs 04.5- 95.5 oil VII-19 6-C H 4-F H i-Pr C2Hs 94.5- 95.5 VII-20 H H 4-F H i-Pr C2Hs 94.5- 95.5 II-21 H H 4-F H c-Pr CH3 113.5- 116.5 II-21 H H 4-OPh H i-Pr C2Hs 96.0- 98.0 II-22 6-C H H	VI - 12	6-C L	Н	2-C L	Н	i-Pr	C ₂ H ₅	
VII-14 н н 3-Me 4-F i-Pr C ₂ H ₅ oil VII-15 H H 3-Me 5-Me i-Pr C ₂ H ₅ oil VII-15 H H 3-Me 5-Me i-Pr C ₂ H ₅ oil VII-15 H H 3-Me 5-Me i-Pr C ₂ H ₅ 96.0-98.0 VII-16 6-OMe 7-OMe 4-F H i-Pr C ₂ H ₅ 96.0-98.0 VII-17 H H 4-F H C ₂ H ₅ CH ₃ 139.0 VII-18 H H 4-F H n-Pr C ₂ H ₅ 0il 139.5 VII-19 6-C L H 4-F H n-Pr C ₂ H ₅ 94.5-95.5 II-20 H H 4-F H i-Pr C ₂ H ₅ 94.5-95.5 II-21 H 4-F H c-Pr CH ₃ 113.5-116.5 II-21 H 4-OPh H i-Pr C ₂ H ₅ 96.0-98.0 II-22 6-C L 8-C L 4-F H i-Pr C ₂ H ₅ 96.0-98.0 II-23 6-C L<	VII - 13	Н	Н	4 - CF 3	Н	i-Pr	CzHs	
VII - 16 6 - 0Me 7 - 0Me 4 - F H i - Pr C_2H_5 96.0 - 98.0 VII - 17 H H 4 - F H C_2H_5 CH ₃ 139.0 139.5 MI - 18 H H 4 - F H n - Pr C_2H_5 oil 139.5 oil MI - 19 6 - C ℓ H 4 - F H n - Pr C_2H_5 94.5 - 95.5 oil MI - 19 6 - C ℓ H 4 - F H i - Pr C_2H_5 94.5 - 95.5 MI - 20 H H 4 - F H c - Pr C II 3 113.5 - 116.5 MI - 21 H H 4 - OPh H i - Pr C 2H_5 96.0 - 98.0 MI - 22 6 - C ℓ 8 - C ℓ 4 - F H i - Pr C 2H_5 96.0 - 98.0 MI - 23 6 - C ℓ H H Ph C 2H_5 118.8	VII - 14	Н	H	3-Me	4 - F	i-Pr	C 2 H 5	
$MI - 17$ H H $4 - F$ H $C_2 H_s$ CH_3 139.0 $MI - 18$ H H $4 - F$ H $n - Pr$ $C_2 H_s$ oil $MI - 19$ $6 - C \ell$ H $4 - F$ H $n - Pr$ $C_2 H_s$ oil $MI - 19$ $6 - C \ell$ H $4 - F$ H $i - Pr$ $C_2 H_s$ $94.5 - 95.5$ $MI - 20$ H H $4 - F$ H $c - Pr$ $C H_3$ $113.5 - 95.5$ $MI - 21$ H H $4 - OPh$ H $i - Pr$ $C_2 H_s$ oil $MI - 22$ $6 - C \ell$ $8 - C \ell$ $4 - F$ H $i - Pr$ $C_2 H_s$ oil $MI - 22$ $6 - C \ell$ $8 - C \ell$ $4 - F$ H $i - Pr$ $C_2 H_s$ $96.0 - 98.0$ $MI - 23$ $6 - C \ell$ H H H Ph $C_2 H_s$ 118.8	VII - 15	Н	H	3-Me	5-Me	i-Pr	C 2 H 5	oil
$M - 17$ H H $4 - F$ H $C_2 H_5$ $C H_3$ 139.0 $M - 18$ H H $4 - F$ H $n - Pr$ $C_2 H_5$ oil $M - 19$ $6 - C \ell$ H $4 - F$ H $n - Pr$ $C_2 H_5$ $94.5 - 95.5$ $M - 19$ $6 - C \ell$ H $4 - F$ H $i - Pr$ $C_2 H_5$ $94.5 - 95.5$ $M - 20$ H H $4 - F$ H $c - Pr$ $C H_3$ $113.5 - 116.5$ $M - 21$ H H $4 - OPh$ H $i - Pr$ $C_2 H_5$ oil $M - 22$ $6 - C \ell$ $8 - C \ell$ $4 - F$ H $i - Pr$ $C_2 H_5$ $96.0 - 98.0$ $M - 23$ $6 - C \ell$ H H H Ph $C_2 H_5$ 118.8	VI - 16	6-0Me	7-0M	e 4-F	Н	i-Pr	C 2 H 5	
$M = 18$ H $4 - F$ H $n - Pr$ $C_2 H_5$ oil $M = 19$ $6 - C\ell$ H $4 - F$ H $i - Pr$ $C_2 H_5$ $94.5 M = 19$ $6 - C\ell$ H $4 - F$ H $i - Pr$ $C_2 H_5$ $94.5 95.5$ $M = 20$ H H $4 - F$ H $c - Pr$ $C H_3$ $113.5 116.5$ 116.5 116.5 01 $M = 21$ H H $4 - OPh$ H $i - Pr$ $C_2 H_5$ $06.0 98.0$ 98.0 98.0 98.0 118.8 118.8 118.8	VI - 17							139.0
П-20 Н Н 4-F Н с-Pr СИз 113.5- 116.5 П-21 Н Н 4-0Ph Н i-Pr C2И5 0il П-22 6-C L 8-C L 4-F Н i-Pr C2H5 96.0- 98.0 П-23 6-C L Н Н Н Рh C2H5 118.8								oil
П-21 Н Н 4-0Ph H i-Pr C ₂ II ₅ oil П-22 6-C L 8-C L 4-F H i-Pr C ₂ II ₅ 96.0- 98.0 П-23 6-C L H H H Ph C ₂ H ₅ 118.8								94.5-
II-21 H H 4-0Ph H i-Pr C ₂ II ₅ oil II-22 6-CL 8-CL 4-F H i-Pr C ₂ H ₅ 96.0- 98.0 II-23 6-CL H H H Ph C ₂ H ₅ 118.8	T - 20	Н	H	4 - F	Н	c-Pr	CII 3	95.5
98.0 I-236-Сен н н Рh СzHs 118.8								oil
II-23 6-02 H H H Ph C ₂ H ₅ 118.8								96.0-
	I-23	6-C l	H	Н	Н	Ph (2 H s	

qc.

Table 4

. .

.

1

I

.1.

(Compounds in this Table are compounds of the formula VII wherein R⁶ is hydrogen.)

45 -

VII - 24 6	5-C L	Н	Н	H	c-Pr	СНз	97.0-
VII - 25	H	Н	4 - F	Н	sec-Bu	СН ₃	98.5 oil
VII-26 6	S-Me	H	4 - F	H	i-Pr	C z II 5	109.0
VI-27 6	-0Me	7-0Me	4 - F	H	c-Pr	CH ₃	-111.0 153.0 -153.5
VI – 8	3						
H - N	MR (in	CDCl ₃) б	ppı	n:		
. 0	.92 (t,3H,J	=7 Hz)	, 1.	.41 (d	6H,J=	6Hz)
2	.47 (s,3H),	3.27	(Heg	otaplet,	1H,J=6H	Iz)
3	.96 (а,2H,J	=7 Hz)	, 7.	0 - 7.	8(m, 8	(H)
VII = 1	4						
H - N I	MR (in	CDCl ₃)	δ	p p m	:		
1.	.01 (t	;,3H,J=	7Hz),	1.4	2 (d,6	H, J=6H	z)
2.	38 (s	,3H,J=	·3Hz),	3.2	5(Hepta	aplet,1H	,J=6Hz)
		,2H,J=					
VI – 15	5						
H - N M	R(in (CDC ² 3)	δ	ppm	:		
0.	97 (t	,3H,J=	7Hz),	1.43	3 (d,6	H, J=6H:	z)
2.	29 (s	,6H),	3.25	Hep	taplet,1	H,J=6H:	z)
4.	00 (q	,2H,J=	7Hz),	6.3	- 8.0(1	n,7H)	

- 46 -

. .

÷.,

I

. 14

```
VII - 18

H-NMR (in CDC^{2}_{3}) \delta ppm :

0.98 (t, 3H, J=7Hz), 1.02 (t, 3H, J=7Hz)

1.6-2.3(m, 2H), 2.8-3.1(m, 2H)

4.03 (q, 2H, J=7Hz), 6.9-8.1(m, 8H)

VI - 21

H-NMR (in CDC^{2}_{3}) \delta ppm :

1.03 (t, 3H, J=7Hz), 1.41 (d, 6H, J=6Hz)

3.25(Heptaplet, 1H, J=6Hz), 4.05(q, 2H, J=7Hz),

6.8-8.1(m, 13H)

VI - 25

H-NMR (in CDC^{2}_{3}) \delta ppm :

0.97 (d, 6H, J=6Hz), 2.0~2.6(m, 1H)

2.85 (d, 2H, J=7Hz), 3.51(s, 3H),
```

- 47 -

Se . 150

.

:

I

In the same manner as in Example 1-b, compounds VI-2 to VI-27 were prepared. (In Table 5, R^1 , R^2 , R^3 , R^4 and R^5 correspond to the substituents in compound VI.)

6.8-8.1(m,8H)

HX

					* 1	
Compour	nd R ¹	R ²	R ³	R⁴	R s	m. p. (℃)
VI - 2	Н	Н	p - F	11	СН з	
VI - 3	Н	Н	Н	Н	CH ₃	149-151
VI - 4	Н	Н	H	Н	i-Pr	130-
VI - 5	6-C L	Н	H	Н	CH ₃	130.5 139-141
VI - 6	6-C L	Н	H	H	i-Pr	168-169
VI - 7	Н	Н	2 - F	Н	i-Pr	140.5-
VI - 8	7-Me	Н	Н	Н	i-Pr	$142.0 \\ 155.0 -$
VI - 9	H	H	4-C L	Н	i-Pr	157.0 192.0-
VI - 10	H	H	4-0Me	H	i-Pr	195.0 186.0-
VI - 11	Н	Н	4-Me	H	i-Pr	188.5 161.0-
VI - 12	6-C L	Н	2-C L	Н	i-Pr	$\begin{array}{c}164.0\\122.0\end{array}$
VI - 13	H	Н	4-CF ₃	Н	i-Pr	124.0 183.0-
VI - 14	Н	Н	3-Me	4 - F	i-Pr	186.0 161.0-
VI - 15	Н	Н	3-Me	5-Me	i-Pr	$162.5 \\ 137.0 -$
VI - 16	6-Me	7-0Me	4 - F	H	i-Pr	$138.0 \\ 164.0 \\ 165.0$
VI - 17	Н	H	4 - F	Н	C 2 H 5	141.5-
VI - 18	Н	Н	4 - F	Н	n-Pr	$143.5 \\ 146.5 $
VI - 19	6-C4	2 11	4 - F	Н	i-Pr	$148.5 \\ 171.0 \\ 172.0$

Tale 5 (Compounds in this Table are compounds of the formula VI wherein R⁶ is hydrogen.)

- 48 -

. .

r

· · ·

**

2.

Ĩ

VI - 20	Н	Н	4 - F	Н	c-Pr	120-126
VI - 21	H	Н	4 - 0 P h	Н	i-Pr	153.0-
VI - 22	6-C L	8-C L	4 - F	H	i-Pr	154.0 98.5-103
VI - 23	6-C L	Н	Н	H	Ρh	171.5-
VI - 24	6-C L	Н	H	Н	c-Pr	172.5 84.0-
VI - 25	Н	Н	4 - F	H	sec-Bu	86.0 119.0-
VI - 26	6-Me	Н	4 - F	Н	i-Pr	121.0 160.0-
VI - 27	6-0Me	7-0Me	4 - F	Н	c-Pr	161.5 162.0- 163.0

49

(

\$

I

In the same manner as in Example 1-c, compounds V-2 to V-27 were prepared. (In Table 6, R^1 , R^2 , R^3 , R^4 and R^5 correspond to the substituents of compound of V.)

Table 6 (Compounds in this Table are compounds of the formula V wherein R⁶ is hydrogen.)

Compoun	d R ¹	R ^z	R ³	R⁴	R ^s	m. p. (°C)
V - 2	Н	Н	p - F	Н	CII 3	125-128
V - 3	H	H	H	H	CII 3	143-146
V - 4	Н	Н	Н	Н	i-Pr	92-93
V - 5	6-C L	Н	Н	H	CH a	220-222

50

Ç

· •

•.'

2.2

Γ,

.1.

- 50 -

	V - 6	6-Cl	Н	н	Н	i-Pr	140-140.5
	V - 7	Н	Н	2 - F	H	i-Pr	121.5-
	V - 8	7-Me	Н	Н	Н	i-Pr	124.0 105.1-
	V - 9	Н	Н	4-C l	Н	i-Pr	$109.2 \\ 147.0 -$
	V -10	Н	Н	4-0Me	Н	i-Pr	$147.8 \\ 135.6 $ -
	V - 11	Н	Н	4-Me	Н	i-Pr	$136.8 \\ 119.4 -$
	V - 12	6-C L	H	2-C L	Н	i-Pr	120.4 105.8-
	V -13	Н	Н	4 - C F 3	Н	i-Pr	$106.9 \\ 163.7 -$
	V - 14	Н	Н	3-Me	4 - F	i-Pr	$164.2 \\ 161.1 -$
	V -15	H	Н	3-Me	5 - M	e i-Pr	108.1 120.8-
	V-16	6-0M	e 7-0Me	4 - F	H	i-Pr	122.3 164.4-
	V - 17	Н	Н	4 - F	H	C ₂ H ₅	$165.2 \\ 143.1 -$
	V -18	Н	Н	4 - F	H	n-Pr	144.2 150.2-
	V -19	6-C L	Н	4 - F	Н	i-Pr	155.3 164.5-
	V-20	Н	Н	4 - F	H	c-Pr	165.3 150.1-
	V - 21	Н	H 4	- 0 P h	Н	i-Pr	151.6 106.9-
	V - 22	6-C L	8-C L	4 - F	Н	i-Pr	107.7 135.0- 125.7
	V - 23	6-C L	Н	Н	Н	Ρh	135.7 174.8-
	V - 24	6-C L	Н	Н	H	c-Pr	175.3 157.5-
	V - 25	Н	Н	4 - F	H s	ec-Bu	158.0 125.0-
	V - 26	6-Me	Н	4 - F	Н	i-Pr	126.5 155.0-
	V - 27	6-0Me	7-0Me	4 - F	Н	c-Pr	157.0 200.0- 200.5
1							

.)

In the same manner as in Example 1-d, compounds IV-2
to IV-6 were prepared. (In Table 7, R^1 , R^2 , R^3 , R^4 and
R ⁵ correspond to the substituents of compound IV.)
Table 7 (Compounds in this Table are compounds of the formula IV wherein R ⁶ is hydrogen.)
Compound R ¹ R ² R ³ R ⁴ R ⁵ m. p. (°C)

- 51 -

. 14

5

Ć

· .

.

L't

I

Jompound	π	<u><u>R</u>-</u>	<u><u> </u></u>	Rª.	R *	<u>m.p.(°C</u>)
IV - 2	H	H	4 - F	H	CH ₃	177-179
IV - 3	Н				СН3	"o" s
IV - 4	Ħ	Н	H	H	i-Pr	
N - 5	6-C L	Н	Н	Н	CH ₃	
<u>IV - 6</u>						

In the same manner as in Example 1-e, compounds III-2 to III-27 were prepared. (In Table 8, R^1 , R^2 , R^3 , R^4 and R^5 correspond to the substituents of compound III.)

- 52 -

Table 8 (Compounds in this Table are compounds of the formula III wherein R⁶ is hydrogen.)

Compour	nd R ¹	R 2	R ³	R 4	R⁵	m. p. (℃)
Ⅲ -2	Н	Н	4 - F	Н	CH 3	194-196
Ш - З	Н	Н	Н	H	СНз	170-
Ⅲ - 4	Н	Н	H	Н	i-Pr	171.5 107-
Ш - 5	6-C l	Н	Н	Н	СН з	108.5 192-194
Ш - б	6-C l	H	H	Н	i-Pr	125.5
Ⅲ - 7	Н	Н	2 - F	Н	i-Pr	-127 80.1
Щ -8	.7-Me	Н	H	Н	i-Pr	-80.2 121.1-
Ⅲ - 9	Н	H	4-C L	H	i-Pr	122.3 148.0-
Щ -10	Н	Н	4-0Me	H	i-Pr	149.1 137.4-
Ⅲ-11	Н	H	4-Me	Н	i-Pr	140.1
Щ -12	6-C L	Н	2-C l	Н	i-Pr	113.1 83.8
Щ -13	Н	H	4 - CF 3	И	i-Pr	-84.5 126.2- 128.8

Sawai Ex 1003 Page 57 of 175

(

•.**

2

I

Щ -14	Н	Н	3-Me	4 - F	i-Pr	124.8-	
Ⅲ-15	H	H	3-Me	5 - M	e i-Pr	126 4	
∏ -16	6-0Me	7 - 0)Me 4-F	H	i-Pr	120.3	
Ш-17	Н	H	4 - F	Н	C ₂ H ₅	150.9 124.3-	
Ⅲ-18	Н	H	4 - F	Н	n-Pr	128.5	
Щ -19	6-C L	H	4 - F	H	i-Pr	121.5	
Ⅲ-20	Н	Н	4 - F	H	c-Pr	135.9	
Ⅲ-21	Н	H	4 - 0 P h		i-Pr	141.3 - 144.1	
Ⅲ-22	6-C L		l 4-F	Н		oil	
Щ-23	6-C L	H	ж ц-г Н		i-Pr	117-	
Ⅲ-24	6-C L	н		H	Ph	142.8 - 144.3	
	0-0 2	n	Н	H	c-Pr	161.0 - 161.5	
Щ-25	Н	Н	4 - F	H s	ec-Bu	78.0-	
Щ -26	6-Me	H	4 - F	H	i-Pr	81.0 137.0-	
Ⅲ-27	6-0Me 7-	0Me	4 - F	Н	c-Pr	137.5 189.5-	
						191.0	

Ⅲ - 2 2

.`.

•."

 Σ_1

Ĩ

. .

1

H-NMR (in $CDCl_3$) δ ppm : 1.40 (d, 6H, J=7Hz), 3.44 (Heptaplet, 1H, J=7Hz) 5.93 (dd, 1H, J=8Hz, J=16Hz), 6.8-8.1 (m, 14H) 9.34 (d, 1H, J=8Hz)

- 53 -

In the same manner as in Example 1-f, compounds II-2 to II-27 were prepared. (In Table 9, R^1 , R^2 , R^3 , R^4 and ${\rm R}^5$ correspond to the substituents of compound II.)

- 54 -

(

. . .

1.4

3

Ĩ

Table 9 (Compounds in this Table are compounds of the formula of II wherein R⁶ is hydrogen.)

Compou	ind R ¹	R 2	R 3	R 4	R 5	R 1 2	m. p. (°C)
∏ -2	H	H	p - F	Н	СНз	C 2 II 5	oil
I - 3	Н	Н	Н	H	СНа	C 2 H 5	105
II - 4	Н	Н	Н	Н	i-Pr	CzH5	-106 88.5
I - 5	6-C2	Н	Н	Н	CH a	CzH5	-90.5 77-82
I - 6	6-C L	H	Н	H	i-Pr		96-98
II - 7	H	H	2 - F	Н		С2Н5	oil
I - 8	7-Me	Н	Н	H		CzHs	68.5-
∏-9	Н	Н	4-C L	Н		CzHs	74.0 91.0
∐ -10	Н	Н	4-0Me	Н	i-Pr		-94.0 78.0
∏ -11	Н	Н	4-0Me	Н	i-Pr		-78.5 75.0
₫ -12	6-C L	Н	2-C L	Н	i-Pr		-78.0
∏ -13	H	Н	4 - CF 3	н			oil
I -14	Н	H	3-Me	4 - F	i-Pr		78.0
I - 15	H	H	3-Me		i-Pr		66.0 -71.0
0			0-ne	0 - 116	i-Pr	U 2 H 5	oil

Sawai Ex 1003 Page 59 of 175

∏ -26	6-CL 6-CL H 6-Me 6-0Me	H H H	H 4 - F 4 - F	H H H	.3	C 2 H 5 C 2 H 5	69.0 -71.0 oil
	6-C L H	H H	H 4 - F	H H	c-Pr sec-Bu	C 2 H 5 C 2 H 5	69.0 -71.0 oil
Ū-25	6-C <i>L</i>	Н	H	H	c-Pr	C 2 H 5	69.0
100.000	6-C <i>L</i>	Н			.3		69.0
II - 24				Н	Ph	CzHs	oil
		IT	Н		24	S	計 · · · · · · · · ·
	26-C <i>L</i>		4 - F	Н	i-Pr	CzHs	125.0 oil
	H			H	i-Pr	C 2 H 5	-93.0
	Э Н		4 - F	Н	c-Pr	C2H5	
	96-Cl	3	4 - F	Н	i-Pr	CzII5	111.0-
	8 H		4 - F	Н	n-Pr	C 2 11 5	-97.0 oil
Ⅱ - 1	7 H	H	4 - F	H	C ₂ H ₅	C ₂ H ₅	-90.0 94.0
∏ -1	6 6-0M	e 7-0M	e 4-F	Н	i-Pr	C 2 H 5	83.0

- 55 -

I - 7

. .

•.*

7

T

H-NMR (in $CDC^{\&}_{3}$) δ ppm : 1.21(t, 3H, J=7Hz), 1.32(d, 6H, J=6Hz) 2.2-2.4(m, 2H), 2.5-2.7(m, 1H) 3.28(s, 1H), 3.34(Heptaplet, 1H, J=6Hz) 4.08(q, 2H, J=7Hz), 4.3-4.6(m, 1H) 5.28(dd, 1H, J=6Hz, J=15Hz), 6.53(dd, 1H, J=1.5Hz, J=15Hz), 6.9-8.0(m, 8H)

Ⅱ - 1 2 H-NMR(in CDC ℓ_3) δ ppm : 1.25(t, 3H, J = 7Hz), 1.33(d, 6H, J = 6Hz)2.2-2.4(m,2H), 2.5-2.8(m,1H) 3.32(s,2H), 3.38(Heptaplet, 1H, J=6Hz) 4.13(q, 2H, J=7Hz), 4.2-4.6(m, 1H)5.34(dd, 1H, J=6Hz, J=15Hz), 6.53(dd, 1H, J=1.5Hz, J=15Hz), 7.0-8.0(m, 7H)II — 1 5 H-NMR(in CDCℓ₃) δ ppm : 1.23(t, 3H, J=7Hz), 1.35(d, 6H, J=6Hz)2.2-2.4(m,2H), 2.31(s,6H) 2.6-2.8(m,1H), 3.32(s,2H) 3.35(Heptaplet,1H,J=6Hz),4.12(q,2H,J=7Hz) 4.3-4.7(m,1H), 5.30(dd,1H,J=6Hz,J=16Hz) 6.51(dd, 1H, J=1Hz, J=16Hz), 6.7-8.0(m, 7H)∏ - 1 8

- 56 -

.1

2.4

1

(

H-NMR (in $CDCl_3$) δ ppm : 1.00(t, 3H, J=7Hz), 1.26(t, 3H, J=7Hz) 1.6-2.3(m, 2H), 2.42(d, 2H, J=6Hz)



2.6-3.2(m, 3H), 3.35(s, 2H) 4.11(q, 2H, J=7Hz), 4.3-4.7(m, 1H) 5.27(dd, 1H, J=6Hz, J=16Hz) 6.46(dd, 1H, J=1.5Hz, J=16Hz), 6.9-8.0(m, 8H) $\Pi - 2 2$ H-NMR(in CDC $\frac{\ell}{3}$) δ ppm : 1.26(t, 3H, J=7Hz), 1.33(d, 6H, J=6Hz) 2.43(d, 2H, J=6Hz), 2.6-2.9(m, 1H)

3.36(s,2H), 3.44 (Heptaplet,1H,J=6Hz)

4.13(q, 2H, J=7Hz), 4.3-4.7(m, 1H)

- 57 -

5.30(dd, 1H, J = 6Hz, J = 16Hz),

6.53 (dd, 1H, J=1.5Hz, J=16Hz), 7.0-7.6 (m, 6H) II - 2 3

H-NMR(in CDCl₃) δ ppm :

. .

.*

2

I

. 14

1.23(t, 3H, J=7Hz), 2.21(d, 2H, J=6Hz)

2.4-2.6(m,1H), 3.25(s,2H)

4.09(q, 2H, J=7Hz), 4.1-4.4(m, 1H)

5.08(dd, 1H, J = 6Hz, J = 16Hz),

6.26 (dd, 1H, J=1.5Hz, J=16Hz), 7.0 \sim 8.0 (m, 13H)

I − 2 5

(

. 74

ſ

- 58 -

I − 2 6

H-NMR (in $CDCl_3$) δ ppm : 1.25(t, 3H, J=7Hz), 1.32(d, 6H, J=6Hz), 2.32(s, 3H), 2.39(d, 2H, J=7Hz), 2.6-3.1(m, 1H), 3.36(s, 2H), 3.41(Heptaplet, 1H, J=6Hz), 4.11(q, 2H, J=7Hz), 4.3-4.7(m, 1H), 5.0-5.5(m, 1H), 6.3-6.7(m, 1H),

6.8-7.9(m,7H)

Ⅱ - 2 7

H-NMR (in CDC ℓ_3) δ ppm : 0.8-1.5(m,4H), 1.26(t,3H, J=7Hz),



2.0-2.9(m,4H), 3.42(s,2H), 3.71(s,3H), 4.00(s,3H), 4.20(q,2H, J=7Hz), 4.4-4.8(m,1H), 5.3-5.8(m,1H), 6.4-6.9(m,1H), 6.58(s,1H), 7.0-7.5(m,5H)

- 59 -

In the same manner as in Example 1-g, compounds I-12 to I-127 were prepared.

Table 10


. 5.

. .

5

I

(



Compound	R 1	R ²	R ³	R ⁴	R⁵	R ¹² n	i. p. (⁰ C) Iass spectrum
I -12	Н	H	4 - F	Н	СНз	a	oil 423,292
I -13	Н	Н	Н	H	CH ₃	Czlls	264.249
I -14		Н	Н	Н	i-Pr	CzHs	97-100
́ I -15 б	- C L	H	Н	H		C 2 H 5	oil



I-16 6-	CL H	Н	Н	i-Pr C ₂ H	5 oil
I-17 H	Н	2 - F	Н	i-Pr C _z H	
I-187-	Me H	Н	Н	i-Pr C ₂ H ₅	
I-19 H	Н	4-C L	Н	i-Pr C ₂ Hs	
I -110 H	Н	4-0Me	H	i-Pr CzHs	94-98
I -111 H	Н	4-Me	Н	i-Pr C ₂ Hs	79-85
I -112 6	-CL H	2-C L	Н	i-Pr CzHs	oil
I-113 H	H	4 - CF 3	H		
I-114 H	Н	3-Me	4 - F	i-Pr C ₂ H ₅	
I-115 H	Н	3-Me	5 - Me	i-Pr CzHs	oil
I -116 6-	OMe 7-01	1e 4-F	Н	i-Pr C ₂ H ₅	gum
I-117 H	H	4 - F	Н	C2H5 C2H5	oil
I-118 H	Н	4 - F	Н	n-Pr CzHs	oil
I -119 6-	CL H	4 - F	Н	i-Pr CzHs	79-82
I-120 H	H	4 - F	Н	c-Pr C ₂ H ₅	100-104
I-121 H	H	4 - 0 P h	H	i-Pr C2H5	oil
I -122 6-0	CL 8-CL	24-F	Н	i-Pr CzHs	
I -123 6-0	CL H	Н	Н	Ph C ₂ H ₅	gum
I-124 6-0	e II	H		c-Pr CzHs	27539 Pb - Pb
I-125 H	Н	4 - F	H se	c-Bu Cells	oil

- 60 -

(

1. j.

I

I -126 6-	Me H	4 - F	Н	i-Pr	Coll-	oil
I -127 6-	0Me 7-0M	e 4-F		c-Pr		gum
I - 1 '	7					
H - NMR	(in CDCl	3) S	ppr	n :		
1.2	9(t,3H,J=	7Hz),]	1.40	(d,6H,	J = 6 Hz)	
1.4	-1.7(m,2H), 2.3-	2.5	(m,2H)		S.
	3.2(m,1H				1H,J=6H	z)
3.5-	3.8(m,1H), 3.9-	4.5	(m,2H)		52 5
4.20	(q,2H,J=	7Hz), 5	. 2 - 3	5.7(m,)	(H)	
	6.9(m,1H)					
I — 1 8		nt ^{an} n	11 76			23
H-NMR (in CDCl ₃)	δρ) p m	:		
1.0-1	4(m,2H)	, 1.31(t,3	H, J=7H	z)	
1.39(d, 6H, J = 6	Hz), 2.	3-2	.5(m,2)	H)	
2.52(s,3H),	3.1-3	.4(r	n,1H)		
3.48(1	Heptaplet,	lH,J≡6Hz	.),3.	5-3.80	(m,1H)	
3.8-4	.1(m,1H),	4.20(0	4,2H	J = 7 H z)	
4.2-4.	.5(m,1H),	5.2-5.	6(m	,1H)		
6.4-6.	8(m,1H),	7.0-8.	0 (m	,8H)		

- 61 -

.1.

.

12

I

(

in the

•."

1

1

- 62 -

C

$$\begin{split} & \text{I} - 19 \\ & \text{H-NMR} (\text{in } \text{CDC} \&_3) \qquad \delta \text{ ppm} : \\ & 1.29(\text{t}, 3\text{H}, \text{J} = 7\text{H}z), \qquad 1.38(\text{d}, 6\text{H}, \text{J} = 6\text{H}z) \\ & 1.4 - 1.8(\text{m}, 2\text{H}), \qquad 2.3 - 2.5(\text{m}, 2\text{H}) \\ & 3.2 - 3.4(\text{m}, 1\text{H}), \qquad 3.49(\text{Heptaplet}, 1\text{H}, \text{J} = 6\text{H}z) \\ & 3.6 - 3.8(\text{m}, 1\text{H}), \qquad 3.9 - 4.2(\text{m}, 1\text{H}) \\ & 4.20(\text{q}, 2\text{H}, \text{J} = 7\text{H}z), \qquad 4.3 - 4.5(\text{m}, 1\text{H}) \\ & 5.2 - 5.5(\text{m}, 1\text{H}), \qquad 6.5 - 6.8(\text{m}, 1\text{H}) \\ & 7.0 - 8.2(\text{m}, 8\text{H}) \\ & \text{I} - 1 \ 1 \ 0 \\ & \text{H-NMR}(\text{in } \text{CDC} \&_3) \qquad \delta \text{ ppm} : \end{split}$$

1.29(t, 3H, J=7Hz), 1.40(d, 6H, J=6Hz)
1.5-1.6(m, 2H), 2.3-2.5(m, 2H)
2.8-3.0(m, 1H), 3.4-3.6(m, 1H)
3.52(Heptaplet, 1H, J=6Hz), 3.88(s, 3H)
3.9-4.1(m, 1H), 4.20(q, 2H, J=7Hz)
4.3-4.5(m, 1H), 5.3-5.5(m, 1H)
6.5-6.7(m, 1H), 6.9-8.1(m, 8H)
I - 1 1 1

H-NMR (in CDC ℓ_3) δ ppm : 1.30(t,3H, J=7Hz), 1.3-1.5(m,2H)



1.39(d,6H,J=6Hz), 2.3-2.5(m,2H)
2.43(s,3H), 2.8-3.0(m,1H)
3.50(Heptaplet,1H,J=6Hz),3.5-3.7(m,1H)
3.9-4.2(m,1H), 4.19(q,2H,J=7Hz)
4.2-4.5(m,1H), 5.2-5.6(m,1H)
6.4-6.8(m,1H), 6.9-8.2(m,8H)

- 63 -

I - 1 1 2

(

H-NMR (in $CDCl_3$) δ ppm : 1.30(t, 3H, J=7Hz), 1.3-1.6(m, 2H) 1.37(d, 6H, J=6Hz), 2.3-2.5(m, 2H) 2.9-3.2(m, 1H), 3.47 (Heptaplet, 1H, J=6Hz) 3.5-3.8(m, 1H), 3.9-4.1(m, 1H) 4.19(q, 2H, J=7Hz), 4.2-4.5(m, 1H) 5.3-5.7(m, 1H), 6.5-6.8(m, 1H) 7.1-8.1(m, 7H)

I - 1 1 3

I

H-NMR(in CDC_{3}^{ℓ}) δ ppm : 1.0-1.3(m,2H), 1.30(t,3H, J=7Hz) 1.40(d,6H, J=6Hz), 2.3-2.4(m,2H) 3.3-3.5(m,1H), 3.49(Heptaplet,1H,J=6Hz)

3.6-3.7(m,1H), 3.9-4.1(m,1H) 4.18(q,2H,J=7Hz), 4.2-4.5(m,1H) 5.1-5.5(m,1H), 6.5-6.8(m,1H) 7.2-8.2(m,8H)

- 64 -

 $I - 1 \ 1 \ 4$

I

H-NMR (in CDC ℓ_3) δ ppm : 1.2-1.4(m,2H), 1.30(t,3H,J=7Hz) 1.39(d,6H,J=6Hz), 2.32(bs,3H) 2.3-2.5(m,2H), 3.0-3.3(m,1H) 3.50(Heptaplet,1H,J=6Hz), 3.6-3.8(m,1H) 3.8-4.1(m,1H), 4.20(q,2H,J=7Hz) 4.3-4.6(m,1H), 5.2-5.6(m,1H) 6.5-6.8(m,1H), 7.0-8.2(m,7H)

 $I - 1 \ 1 \ 5$

H-NMR (in CDC_{3}^{ℓ}) δ ppm : 1.1-1.4(m,2H), 1.30(t,3H, J=7Hz) 1.40(d,6H, J=6Hz), 2.2-2.5(m,2H) 2.35(s,6H), 2.7-3.1(m,1H) 3.51(Heptaplet,1H,J=6Hz), 3.6-3.7(m,1H) 3.8-4.1(m,1H), 4.20(q,2H, J=7Hz)

> Sawai Ex 1003 Page 69 of 175

- 65 -

C

C

T

 $\begin{array}{ll} \text{H-NMR}(\text{in CDC}\,\mathcal{A}_{3}) & \delta & \text{ppm} : \\ 1.30(t, 3\text{H}, J=7\text{H}z), & 1.37(t, 3\text{H}, J=7\text{H}z) \\ 1.4-1.7(m, 2\text{H}), & 2.2-2.6(m, 2\text{H}) \\ 2.8-3.2(m, 3\text{H}), & 3.6-3.9(m, 1\text{H}) \\ 3.9-4.7(m, 4\text{H}), & 5.2-5.7(m, 1\text{H}) \\ 6.3-6.7(m, 1\text{H}) & 7.0-8.2(m, 8\text{H}) \end{array}$



I - 118 H-NMR (in CDC23) δ ppm : 1.01(t, 3H, J=7Hz), 1.27(t, 3H, J=7Hz) 1.4-2.1(m,4H), 2.3-2.6(m,2H) 2.8-3.3(m,3H), 3.6-3.8(m,1H) 3.9-4.1(m, 1H), 4.18(q, 2H, J=7Hz)4.2-4.5(m,1H) 5.2-5.6(m,1H) 6.4-6.7(m,1H), 7.0-8.1(m,8H) $I = 1 \cdot 1 \cdot 9$ H-NMR (in $CDC\ell_3$) δ ppm : 1.2-1.5(m, 2H), 1.31(t, 3H, J=7Hz)1.37(d, 6H, J = 7Hz), 2.3 - 2.6(m, 2H)3.0-3.4(m,1H), 3.49(Heptaplet,1H,J=6Hz) 3.6-3.8(m,1H), 3.8-4.2(m,1H) 4.20(q, 2H, J=7Hz), 4.3-4.5(m, 1H)5.2-5.6(m,1H), 6.4-6.8(m,1H) 7.0-8.1(m,7H) I - 1 2 0H-NMR (in CDC ℓ_3) δ ppm :

- 66 -

.

1

0.8-1.8(m,6H), 1.30(t,3H,J=7Hz) 2.1-2.6(m,3H), 2.9-3.3(m,1H)

- 67 -

. .

•.

.

Ĩ

.1.

(

1.41(d, 6H, J=6Hz), 2.3-2.5(m, 2H)
2.9-3.4(m, 1H), 3.50(Heptaplet, 1H, J=6Hz)
3.6-3.8(m, 1H), 3.9-4.5(m, 2H)
4.20(q, 2H, J=7Hz), 5.2-5.6(m, 1H)
6.4-6.8(m, 1H), 7.1-7.3(m, 5H)

7.72(d, 1H, J=6Hz)I - 1 2 3H-NMR (in CDC l_3) δ ppm : 0.8-1.5(m, 2H), 1.29(t, 3H, J=7Hz)2.2-2.4(m,2H), 2.6-2.9(m,1H) 3.2-3.6(m,1H), 3.7-4.3(m,2H) 4.17(q, 2H, J = 7Hz), 5.0 - 5.4(m, 1H)6.1-6.5(m,1H), 7.0-8.2(m,13H) I - 1 2 4H-NMR (in CDC ℓ_3) δ ppm : 0.8 - 1.8(m, 6H), 1.29(t, 3H, J = 7Hz), 2.2-2.6(m,3H), 2.8-3.2(m,1H), 3.3-3.7(m,1H), 3.9-4.5(m,2H), 4.19(q, 2H, J=7Hz), 5.4-5.8(m, 1H),6.5-6.8(m,1H), 7.1-8.0(m,8H), I - 1 2 5 H-NMR (in $CDCl_3$) δ ppm : 0.94(d, 6H, J=6Hz), 1.0-1.7(m, 3H),1.27(t, 3H, J=7Hz), 1.9-2.5(m, 3H),2.90(d, 2H, J = 7Hz), 3.3 - 4.4(m, 3H),

- 68 -

. 1 .

1

4.12(q, 2H, J=7Hz), 5.0-5.5(m, 1H), 6.2-6.7(m, 1H), 6.9-8.0(m, 8H),
I - 1 2 6
H-NMR (in CDC 23) δ ppm : 1.0-1.6(m, 3H), 1.21(t, 3H, J=7Hz),
1.34(d, 6H, J=6Hz), 2.34(s, 3H),
2.37(d, 2H, J=7Hz), 2.9-3.7(m, 2H),
3.8-4.5(m, 2H), 4.15(q, 2H, J=7Hz),
5.0-5.5(m, 1H), 6.3-6.7(m, 1H),
6.9-8.0(m, 7H),

I - 1 2 7

, te

•.

-

1

H-NMR (in CDC 2_3) δ ppm : 0.8-1.9(m,8H), 1.29(t,3H, J=7Hz), 2.1-2.6(m,3H), 2.8-3.2(m,1H), 3.72(s,3H), 4.02(s,3H), 4.19(q,2H, J=7Hz), 4.3-4.6(m,1H), 5.4-5.8(m,1H), 6.4-6.8(m,1H), 6.56(s,1H), 7.0-7.4(m,5H)

In the same manner as in Exmple 2, compounds I-52 to I-527 were prepared.



(

- 70 -

Table 11


a .

•.

**

I

. t ··



Compoun	d R'	R ²	R ³	R 4	R ⁵	R ¹²	m.p. (°C)
I -52	Н	Н	4 - F	H	CH ₃	Na	138-142
I - 53	H	H	Н	Н	СН 3	Na	(decomposed) 130-132
I -54	Н	Н	Н	Н	i-Pr	Na	(decomposed) 196-197
I -55	6-C L	H	H	Н	СНз	Na	(decomposed) 211-215
I - 56	6-C L	Н	H	H	i-Pr	Na	(decomposed) 195-198 (decomposed)
I - 57	Н	Н	2 - F	Н	i-Pr	Na	(decomposed) 193-201 (decomposed)
I - 58	7-Me	Н	Н	Н	i-Pr	Na	170-175
I -59	Н	Н	4-C L	Н	i-Pr	Na	(decomposed) 193-202
I -510	Н	H	4-0Me	Н	i-Pr	Na	(decomposed) 178-193
							(decomposed)
I -511	Н	Н	4-Me	Н	i-Pr	Na	187-200
`*							(decomposed)

7.1

I - 5	12	6-C l	Н	2-C l	Н	: г	. N	
1 5	0			2 0 0	1	1 - 1	r Na	
I - 51		Н	Н	4-CF3	: H	i - P	'r Na	(decomposed) 200-212
I -51		Н	Н	3-Me	4 - 1	Fi-P	r Na	(decomposed) 195-200
I -51	5	Н	Н	3-Me	5 - 1	1e i-P	r Na	(decomposed) 192-197
I -51	6	6-0Me	7-0Me	4 - F	H	i - P	r Na	(decomposed)
I -51	7	Н	Н	4 - F	H	C 2 H	s Na	(decomposed) 230-237
I - 51	8	Н	Н	4 - F	H -	n - P 1	• Na	(decomposed) 193-200
1 - 519	96	5-CL	Н	4 - F	H	i-Pr	Na	(decomposed) 193-198
I -520)	Н	Н	4 - F	H	c-Pr	Na	(decomposed) 197-199
I -521		Н	Н	4 - 0 P h	H	i-Pr	Na	(decomposed) 180-189
I -522	6	- C L	8-C l	4 - F	H	i-Pr	Na	(decomposed) 183-187
I -523	6	-Cl	Н	Н	H	Ph	Na	(decomposed) 190-196
I -524	6 -	-CL	H	Н	H	c-Pr	Na	(decomposed) 204-210
I -525		H	Н	4 - F	H	sec-Bu	Na	(decomposed)
I -526	6 -	Me	Н	4 - F	H	i-Pr	Na	204-208
I -527	6 -	OMe	7-0Me	4 - F	Н	c-Pr	Na	(decomposed) 234-238
 	et e te data							(decomposed)

I = 5 7

.

••••

Ĩ

H-NMR (in DMSO-d⁶) d ppm :

0.9-1.2(m,2H), 1.37(d,6H,J=7Hz)

4

- 71 -

1.6-2.1(m,2H), 3.48(Heptaplet,1H,J=6Hz) 3.7-4.3(m,4H), 5.3-5.6(m,1H) 6.4-6.7(m,1H), 7.1-8.1(m,8H) I - 5 8H-NMR (in DMSO-d⁶) δ ppm : 0.9-1.2(m, 2H), 1.31(d, 6H, J=7Hz)1.7-2.2(m,2H), 2.50(s,3H) 3.3-4.5(m,5H), 5.2-5.6(m,1H) 6.3-6.6(m,1H), 7.1-7.9(m,8H) I - 5 9H-NMR (in DMSO-d⁶) δ ppm : 0.9-1.3(m, 2H), 1.33(d, 6H, J=7Hz)1.6-2.2(m,2H), 3.48(Heptaplet,1H,J=7Hz) 3.5-4.6(m,4H), 5.2-5.6(m,2H) 6.3-6.6(m,1H), 7.1-8.1(m,8H) I - 5 1 0 H-NMR (in DMSO-d⁶) δ ρpm : 1.0-1.3(m,2H), 1.32(d,6H,J=7Hz) 1.6-2.2(m,2H), 3.0-3.8(m,4H) 3.86(s,3H), 4.0-4.3(m,1H)

- 72 -

(

•.*

I

73

5.3-5.6(m,1H), 6.3-6.6(m,1H) 6.9-8.1(m,8H) I - 5 1 1 H-NMR (in DMSO-d⁶) & ppm : 0.9-1.3(m, 2H), 1.33(d, 6H, J=7Hz)1.7-2.1(m,2H), 2.41(s,3H) 3.2-4.3(m,5H), 5.3-5.6(m,1H) 6.3-6.6(m,1H), 7.0-8.3(m,8H) I = 5 1 2H-NMR (in DMSO-d⁶) δ ppm : 0.9-1.3(m, 2H), 1.33(d, 6H, J=7Hz)1.6-2.2(m,2H), 3.1-3.8(m,3H) 3.48(Heptaplet,1H,J=7Hz), 3.9-4.2(m,1H) 5.3-5.7(m,1H), 6.3-6.7(m,1H) 7.0-8.1(m,7H) I — 5 1 3 H-NMR (in DMSO-d⁶) δ ppm : 0.8-1.3(m, 2H), 1.34(d, 6H, J = 7Hz)

- 73 -

•.*

.

I

1.6-2.2(m,2H), 2.7-3.9(m,3H)

3.49(Heptaplet,1H,J=7Hz),3.9-4.3(m,1H)

5.2-5.6(m,1H), 6.3-6.7(m,1H) 7.1-8.1(m,8H) I - 5 1 4H-NMR (in DMSO-d⁶) d ppm : 0.9-1.3(m,2H), 1.35(d,6H,J=7Hz) 1.7-2.1(m, 2H), 2.30(d, 3H, J=2Hz)3.0-3.8(m, 3H), 3.51(Heptaplet, 1H, J=7Hz) 3.9-4.3(m,1H), 5.3-5.6(m,1H) 6.3-6.6(m,1H), 6.9-8.1(m,7H) II - 5 1 5 H-NMR (in DMSO-d⁶) δ ppm : 1.0-1.2(m, 2H), 1.35(d, 6H, J=7Hz)1.6-2.2(m,2H), 2.35(s,6H) 3.0-3.8(m, 3H), 3.51(Heptaplet, 1H, J=7Hz) 4.0-4.3(m,1H), 5.3-5.6(m,1H) 6.3-6.6(m,1H), 6.8-8.0(m,7H) I = 5 1 6H-NMR (in DMSO-d⁶) δ ppm : 0.9 - 1.3(m, 2H), 1.31(d, 6H, J = 7Hz)1.7-2.0(m,2H), 3.2-3.7(m,4H)

- 74 -

. . .

T



3.62(s,3H), 3.9-4.2(m,1H) 3.94(s,3H), 5.1-5.5(m,1H) 6.2-6.6(m,1H), 7.0-7.5(m,6H) I - 5 1 7H-NMR (in DMSO-d⁶) δ ppm : 0.9-1.5(m, 2H), 1.34(t, 3H, J=7Hz)1.6-2.2(m,2H), 2.7-3.4(m,4H) 3.6-4.3(m,2H), 5.2-5.7(m,1H) 6.1-6.6(m,1H), 6.9-8.1(m,8H) I - 5 1 8H-NMR (in DMSO-d⁶) δ ppm : 0.8-1.3(m, 2H), 1.01(t, 3H, J=7Hz)1.6-2.1(m,4H), 2.7-3.8(m,5H) 3.9-4.3(m,1H), 5.2-5.7(m,1H) 6.3-6.6(m,1H), 7.1-8.1(m,8H) I - 5 1 9H-NMR (in DMSO-d⁶) δ ppm : 0.9 - 1.3(m, 2H), 1.33(d, 6H, J = 7Hz)1.6-2.2(m,2H), 2.9-3.9(m,3H) 3.49(Heptaplet,1H,J=7Hz),4.0-4.3(m,1H)

- 75 -

.1.

. '

T

1



5.3-5.6(m,1H), 6.3-6.6(m,1H) 7.2-8.1(m,7H) I = 5 2 00.8-1.5(m,6H), 1.7-2.2(m,2H) 2.3-2.7(m,1H), 3.0-3.9(m,3H) 4.0-4.3(m,1H), 5.5-5.8(m,1H) 6.4-6.7(m,1H), 7.2-8.0(m,8H) I - 5 2 1H-NMR (in DMSO-d⁶) δ ppm : 0.9-1.5(m, 2H), 1.36(d, 6H, J=7Hz)1.7-2.3(m,2H), 3.0-3.9(m,3H) 3.50(Heptaplet,1H,J=6Hz),4.0-4.3(m,1H) 5.2-5.6(m,1H) 6.4-6.7(m,1H) 7.0-8.1(m,13H) I - 5 2 2H-NMR (in DMSO-d⁶) δ ppm : 0.8-1.3(m, 2H), 1.37(d, 6H, J = 7Hz)1.6-2.2(m,2H), 3.1-3.9(m,3H) 3.51(Heptaplet,1H,J=7Hz),4.0-4.3(m,1H)

- 76 -

`•`

. *

÷.

1

41.

5.3-5.7(m,1H),	6.3-6.7(m,1H)
7.1-8.0(m,6H)	
I — 5 2 3	
H-NMR (in DMSO-d ⁶) δ ppm :
0.8-1.4(m,2H),	1.6-2.1(m,2H)
2.9-3.7(m,3H),	3.7-4.1(m,1H)
5.1-5.4(m,1H),	6.1-6.4(m,1H)
. 7.1-8.2(m,13H)	ж.
I — 5 2 4	
H-NMR (in DMSO-d ⁶)	δ ppm :
0.8-1.5(m,5H),	1.6-2.2(m,2H)
2.3-2.7(m,2H),	3.0-3.8(m,3H)
3.9-4.3(m,1H),	5.4-5.8(m,1H)
6.3-6.6(m,1H),	7.0-8.0(m,8H)
I — 5 2 5	
H-NMR (in DMSO-d ⁶)	δ ppm :
0.9-1.6(m,2H),	0.96(d,6H,J=6Hz)
1.7-2.6(m,3H),	2.89(d, 2H, J = 7Hz)
3.0-3.8(m,3H),	3.9-4.2(m,1H)
5.2-5.6(m,1H),	6.2-6.6(m,1H)

- 77 -

ii.

.

.*;

I

7.1-8.1(m,8H) I - 5 2 6H-NMR (in DMSO-d⁶) δ ppm : 1.30(d, 6H, J=7Hz), 1.7-2.0(m, 2H),2.34(s,3H), 2.4-2.6(m,1H), 3.0-3.3(m,2H), 3.3-3.8(m,3H) 3.9-4.2(m,1H), 5.2-5.6(m,1H) 6.3-6.6(m,1H), 7.0-8.0(m,7H) I - 5 2 7H-NMR (in DMSO-d⁶) δ ppm : 0.7-1.5(m,5H), 1.8-2.2(m,2H), 2.2-2.6(m,2H), 3.1-3.3(m,2H), 3.59(s,3H), 3.9-4.2(m,2H), 3.91(s,3H), 5.4-5.7(m,1H) 6.3-6.6(m,1H), 6.52(s,1H), 7.0-7.4(m,5H)

> Sawai Ex 1003 Page 83 of 175

ſ

- 78 -

In the same manner as in Example 3, compounds I-22 to I-26 can be prepared.

- 79 -

(

Table 12

(




. .


. *

I

1.64



R¹ Compound \mathbb{R}^2 R³ R⁴ Rs I - 22 H Н 4-F H СНз I - 23 H H H Н CH3 I - 24H H Н H i-Pr I - 256-C & H H H CH3 <u>6-Сен</u> I - 26H H i-Pr



In the same manner as in Example 4, compounds 1-32 to I-36 can be prepared.

- 80 -

Table 13

12

ſ

						OH	
			R³	•	R ⁴	~	
	(5	2 ⁶ = []		$\overline{\gamma}$	ſ		
		1	L'	2		000	
	R 1	Y	~	L			
	R ²	F	DI(N		I - 3	
		1		N	R ⁵		
Compound	R ¹	R ²	R ³	R 4	R⁵	0	
I - 32	Н	Н	4 - F	H	СНз	5 S	
I - 33	H	Н	Н	H	СНз		
I — 34	Н	H	Н	H	i-Pr		
I — 35	6-C L	H	H	H	СНз		2.7
<u> </u>	6-C l	H	H	Н	i-Pr		

	- 81 -				
FORI	MULATION EXAMPLE 1	ā ,			
Tab	lets				
	Compound I-51	1.	0	g	
	Lactose	5.	0	g	
	Crystal cellulose powder	8.	0	g	
	Corn starch	3.	0	g	
	Hydroxypropyl cellulose	l.	0	g	
	CMC-Ca	1.	5	g	
	Magnesium stearate	0.	5	g	uir.
		10			
	Total	20.0	С	g	

The above components were mixed by a usual method and then tabletted to produce 100 tablets each containing 10 15 mg of the active ingredient.

FORMULATION EXAMPLE 2

Capsules

Total	
Magnesium stearate	0.5
Crystal cellulose powder	10.0 g
Lactose	3.5 g
Compound I-51	1.0 g

25

20


St

5

10

Ĩ

The above components were mixed by a usual method and then packed in No. 4 gelatin capsules to obtain 100 capsules each containing 10 mg of the active ingredient.



FORMULATION EXAMPLE 3

Soft capsules

Total

٠,

.`

1

5

/10

Compound I-51	1.00 g
PEG (polyethylene glycol) 400	3.89 g
Saturated fatty acid triglyceride	15.00 g
Peppermint oil	0.01 g
Polysorbate 80	0.10 g
N	

- 82 -

The above components were mixed and packed in No. 3 soft gelatin capsules by a usual method to obtain 100 soft capsules each containing 10 mg of the active ingredient. FORMULATION EXAMPLE 4

15 Ointment

 Compound I-51
 1.0 g (10.0 g)

 Liquid paraffin
 10.0 g (10.0 g)

 Cetanol
 20.0 g (20.0 g)

 White vaseline
 68.4 g (59.4 g)

 Ethylparaben
 0.1 g (0.1 g)

 L-menthol
 0.5 g (0.5 g)

Total

100.0 g

20.00 g

25 The above components were mixed by a usual method to obtain a 1% (10%) ointment. FORMULATION EXAMPLE 5

Suppository

. .

5

10

Compound I-51	1.0 g
Witepsol H15*	46.9 g
Witepsol W35*	52.0 g
Polysorbate 80	0.1 g

- 83 -

Total

100.0 g

l mg

5 ml

*: Trademark for triglyceride compound

The above components were melt-mixed by a usual method and poured into suppository containers, followed by cooling for solidification to obtain 100 suppositories of 1 g each containing 10 mg of the active component.

15 FORMULATION EXAMPLE 6

Injection formulation

Compound I-51

Distilled water for

injection formulation

20

I

The formulation is prepared by dissolving the compound in the distilled water whenever it is required.

	- 84 -	
FC	DRMULATION EXAMPLE 7	
Gr	canules	
	Compound I-51	1.0 g
	Lactose	6.0 g
5	Crystal cellulose powder	6.5 g
	Corn starch	5.0 g
	Hydroxypropyl cellulose	1.0 g
	Magnesium stearate	0.5 g
iv-	2 2	
10	Total	20.0 g

125

1

The above components were granulated by a usual method and packaged to obtain 100 packages each containing 200 mg of the granules so that each package contains 10 mg of the 15 active ingredient.



1. A compound of the formula:

We CLA

5

25

or

I

- R^{3} R^{4} R^{2} Y-Z R^{1} R^{5}
- wherein \mathbb{R}^{1} , \mathbb{R}^{2} , \mathbb{R}^{3} , \mathbb{R}^{4} and \mathbb{R}^{6} are independently hydrogen, C_{1-6} alkyl, C_{1-6} cycloalkyl, C_{1-3} alkoxy, n-butoxy, 10 i-butoxy, sec-butoxy, $\mathbb{R}^{7}\mathbb{R}^{8}N$ (wherein \mathbb{R}^{7} and \mathbb{R}^{8} are independently hydrogen or C_{1-3} alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, pydroxymethyl or $-O(CH_{2})_{2}OR^{19}$

85 -

([)

- -15 (wherein R^{19} is hydrogen or C_{1-3} alkyl, and l is 1, 2 or 3); or when located at the ortho position to each other, R^1 and R^2 , or R^3 and R^4 together form -CH=CH-CH=CH-; or when located at the ortho position to each other, R^1 and R^2 together form -OC(R^{15})(R^{16})O-
- 20 (wherein R¹⁵ and R¹⁶ are independently hydrogen or C₁₋₃ alkyl); Y is -CH₂-, -CH₂CH₂-, -CH=CH-, -CH₂-CH=CH- or -CH=CH-CH₂-; and Z is -Q-CH₂WCH₂-CO₂R¹²,

RI HO RII R' C0 2 R 1 2 RIS

Sawai Ex 1003 Page 90 of 175


	- 86 -
	(wherein Q is $-C(0)$, $-C(OR^{13})_2$ or $-CH(OH)$; W is $-C(0)$,
	$-C(OR^{13})_2$ or $-C(R^{11})(OH)$; R^{11} is hydrogen or C_1 alkyl:
	R^{12} is hydrogen or R^{14} (wherein R^{14} is physiologically
	hydrolyzable alkyl or M (wherein M is NH_4 , sodium,
5	potassium, 1/2 calcium or a hydrate of lower alkylamine,
	di-lower alkylamine or tri-lower alkylamine)); two R ¹³ are
	independently primary or secondary C_{1-6} alkyl; or two R^{13}
	together form $-(CH_2)_2$ or $-(CH_2)_3$; R ¹⁷ and R ¹⁸ are
	independently hydrogen or C_{1-3} alkyl; and R^5 is
10	hydrogen, C ₁₋₆ alkyl, C ₂₋₃ alkenyl, C ₃₋₆ cycloalkyl,
	$(wherein R^9 is hydrogen, C_{1-4}^{P} alkyl, C_{1-3})$
15	alkoxy, fluoro, chloro, bromo or trifluoromethyl),
	phenyl-(CH_2) _m - (wherein m is 1, 2 dr 3),
	$-(CH_2)_n CH(CH_3)$ -phenyl or phenyl- $(CH_2)_n CH(CH_3)$ - (wherein n
	is 0, 1 or 2).
	2. The compound according to Claim 1, wherein in the
20	formula I, R^1 , R^2 and R^6 are independently hydrogen,
	fluoro, chloro, bromo, C1-3 alkyl, C1-3 alkoxy, C3-6
	cycloalkyl, dimethylamino, hydroxy, hydroxymethyl,
×.	hydroxyethyl, trifluoromethyl, trifluoromethoxy,
	difluoromethoxy, phenoxy or benzyloxy; or when R ⁶ is
25	hydrogen, R^1 and R^2 together form methylenedioxy; when R^4
	is hydrogen, R ³ is hydrogen, 3'-fluoro, 3'-chloro,
	3'-methyl, 4'-methyl, 4'-chloro or 4'-fluoro; or R^3 and R^4
	together represent 3'-methyl-4'-chloro, 3',5'-dichloro,
	3',5'-difluoro, 3',5'-dimethyl or 3'-methyl-4'-fluoro; R ⁵
	is primary or

,21

I

secondary C_{1-6} alkyl or C_{3-6} cycloalkyl; and Y is $-CH_2-CH_2$ or -CH=CH-; and Z is

87 -



5

 $-CH(OH)CH_2CH(OH)CH_2CO_2R^{12}, -CH(OH)CH_2C(O)CH_2CO_2R^{12} \text{ or } -CH(OH)CH_2C(OR^{13})_2CH_2CO_2R^{12}.$

3. Compound according to Claim 2, wherein when R² and R⁶ are both hydrogen, R¹ is hydrogen, 5-fluoro, 6-fluoro, 7-fluoro, 8-fluoro, 5-chloro, 6-chloro, 7-chloro, 8-chloro, 5-bromo, 6-bromo, 7-bromo, 8-bromo, 5-methyl, 6-methyl, 7-methyl, 8-methyl, 5-methoxy, 6-methoxy, 7-methoxy, 8-methoxy, 5-trifluoromethyl,

- 15 6-trifluoromethyl, 7-trifluoromethyl, 8-trifluoromethyl, 6-trifluoromethoxy, 6-difluoromethoxy, 8-hydroxyethyl, 5-hydroxy, 6-hydroxy, 7-hydroxy, 8-hydroxy, 6-ethyl, 6-n-butyl or 7-dimethylamino; when R⁶ is hydrogen, R¹ and R² together represent 6-chloro-8-methyl,
- 20 6-bromo-7-methoxy, 6-methyl-7-chloro, 6-chloro-8-hydroxy,
- 5-methyl-2-hydroxy, 6-methoxy-7-chloro, 6-chloro-7-methoxy, 6-hydroxy-7-chloro, 6-chloro-7-hydroxy, 6-chloro-8-bromo, 5-chloro-6-hydroxy, 6-bromo-8-chloro, 6-bromo-8-hydroxy, 5-methyl-8-chloro,
- 25 7-hydroxy-8-chloro, 6-bromo-8-hydroxy, 6-methoxy-7-methyl, 6-chloro-8-bromo, 6-methyl-8-bromo, 6,7-difluoro,

Sawai Ex 1003 Page 92 of 175

- 88 -6,8-difluoro, 6,7-methylenedioxy, 6,8-dichloro, 5,8-dimethyl, 6,8-dimethyl, 6,7-dimethoxy, 6,7-diethoxy, 6,7-dibromo or 6,8-dibromd; or R^1 , R^2 and R^3 together represent 5,7-dimethoxy-8-hydroxy, 5,8-dichloro-6-hydroxy, 6,7,8-trimethoxy, 6,7,8-trimethyl, 6,7,8-trichloro, 5 5-fluoro-6,8-dibromo or 5-chloro-6,8-dibromo; when R^3 is hydrogen, R⁴ is hydrogen, 4 -methyl, 4'-chloro or 4'-fluoro; or when both R^3 and R^4 are not hydrogen, they represent 3',5'-dimethyl or 3'-methyl-4'-fluoro; and Y is 10 -CH₂-CH₂- or (E)--CH=CH-. 4. The compound according to Claim 3, wherein when both R^2 and R^3 are hydrogen, R^1 is hydrogen, 6-methyl, 6-ethyl, 6-n-butyl, 6-trifluoromethyl, 6-chloro, 6-bromo, 6-hydroxy, 6-methoxy or 7-dimethylamino; or when R⁶ is 15 hydrogen, R^1 and R^2 together represent 6,8-dichloro, 5,8-dimethyl, 6,8-dimethyl, 6,7+dimethoxy, 6,7-diethoxy, 6,7-dibromo, 6,8-dibromo, 6,7-difluoro or 6,8-difluoro; when R³ is hydrogen, R⁴ is hydrogen, 4'-fluoro or 4'-chloro; or R^3 and R^4 together represent 20 3'-methyl-4'-fluoro; R⁵ is ethyl, n-propyl, i-propyl or cyclopropyl; and Y is (E)--CH=CH-. 5. The compound according to Claim 3, wherein when both R^2 and R^6 are hydrogen, R^1 is hydrogen, 6-methyl or 6-chloro; or when R^6 is hydrogen, R^1 and R^2 together 25 represent 6,7-dimethoxy; when R^3 is hydrogen, R^4 is hydrogen, 4'-chloro or 4'-fluoro; R⁵ is i-propyl or cyclopropyl; and Y is (E)--CH=CH-.

T

6. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with

- 89 -

- 5 hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid 7. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid,
- 10 a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 8. The compound according to Claim 1, which is

(E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''-

15 methylethyl)-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

9. The compound according to Claim 1, which is

1

- 20 (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.
- 25 10. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4]-04''-fluorophenyl)-2'-cyclopropylquinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the

condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

- 90 -

11. The compound according to Claim 1, which is

- 5 (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-cyclopropyl-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.
- 10 12. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluoropheny1)-2'-cyclopropy1-6'-methyl-quinolin-3'-y1]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alky1
- 15 ester of the carboxylic acid. 13. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-cyclopropyl-6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid

1

- 20 with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 14. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(1''methylethyl)-quinolin-3'-yl]-hept-6-epoic acid, a lactone
- 25 formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

15. The compound according to Claim 1, which is
(E)-3,5-dihydroxy-7-[4'-(4''-chloropheny1)-2'-(1''methylethy1)-6'-chloro-quinolin-3'-y1]-hept-6-enoic acid,
a lactone formed by the condensation of the carboxylic

91 -

5

I

acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 16. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(1''methylethyl)-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid,

- 10 a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 17. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-(1''-
- 15 methylethyl)-6',7'-dimethoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 18. The compound according to Claim 1, which is
- 20 (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-cyclopropylquinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.
- 25 19. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-cyclopropyl-6'-chloro-quinolin-3'-yl]-hept-6-enoic acid, a lactone

formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

20. The compound according to Claim 1, which is

- 5 (E)-3,5-dihydroxy-7-[4'-(4''-chlorophenyl)-2'-cyclopropyl-6'-methyl-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.
- 10 21. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-chloropheny1)-2'-cyclopropy1-6'7'-dimethoxy-quinolin-3'-y1]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃
- 15 alkyl ester of the carboxylic acid. 22. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-methylethyl)quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the
- 20 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

I

23. The compound according to Claim 1, which is
(E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-methylethyl)6'-chloro-quinolin-3'-yl]-hept-6-epoic acid, a lactone

25 formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

- 92 -

24. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-phenyl-2'-(l''-methylethyl)-6'methyl-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.

- 93 -

5

I

25. The compound according to Claim 1, which is
(E)-3,5-dihydroxy-7-[4'-phenyl-2'-(1''-methylethyl)6',7'-dimethoxy-quinolin-3'-yl)-hept-6-enoic acid, a

- 10 lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid. 26. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-quinolin-
- 15 3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or q₁₋₃ alkyl ester of the carboxylic acid.

27. The compound according to Claim 1, which is

- 20 (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-6'-chloroquinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5₇position, or a sodium salt or C₁₋₃ alkyl ester of the carboxylic acid.
- 25 28. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-6'-methylquinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the

condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

- 94 -

29. The compound according to Claim 1, which is

5

(E)-3,5-dihydroxy-7-[4'-phenyl-2'-cyclopropyl-6',7'dimethoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

- 10 30. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-(1''methylethyl)-6'-methoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with hydroxy at the 5-position, or a sodium salt or
- 15 C₁₋₃ alkyl ester of the carboxylic acid. 31. The compound according to Claim 1, which is (E)-3,5-dihydroxy-7-[4'-(4''-fluorophenyl)-2'-cyclopropyl-6'-methoxy-quinolin-3'-yl]-hept-6-enoic acid, a lactone formed by the condensation of the carboxylic acid with
- 20 hydroxy at the 5-position, or a sodium salt or C_{1-3} alkyl ester of the carboxylic acid.

32. An anti-hyperlipidemia agent containing the compound of the formula I as defined in Claim 1.

33. An anti-hyperlipoproteinemia agent containing the

25 compound of the formula I as defined in Claim 1.

34. An anti-atherosclerosis agent containing the compound of the formula I as defined in Claim 1.

35. A method for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis, which comprises administering an effective amount of the compound of the formula I as defined in Claim 1.

- 95 -






compound of the formula:

ABSTRACT


5



(1)

wherein R¹, R², R³, R⁴ and R⁶ are independently hydrogen, C_{1-6} alkyl, C_{1-6} cycloalkyl, C_{1-3} alkoxy, n-botoxy, 10 i-botoxy, sec-butoxy, R⁷R⁸N- (wherein R⁷ and R⁸ are independently hydrogen or C_{1-3} alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-t-butylsilyloxy, hydroxymethyl or $-O(CH_2)_{\ell}OR^{19}$

- 15 (wherein R¹⁹ is hydrogen or C₁₋₃ alkyl, and l is 1,2 or 3); or when located at the ortho position to each other, R¹ and R², or R³ and R⁴ together form -CH=CH-CH=CH-; or when located at the ortho position to each other, R¹ and R² together form -OC(R¹⁵)(R¹⁶)O-20 (wherein R¹⁵ and R¹⁶ are independently hydrogen or C₁₋₃
 - alkyl); Y is $-CH_2^-$, $-CH_2^-CH_2^-$, $-CH=CH^-$, $-CH_2^-CH=CH^-$ or $-CH=CH^-CH_2^-$; and Z is $-Q^-CH_2^-WCH_2^-CO_2^-R^{12}$,



25

5.5

Ĩ

or

(wherein Q is -C(0)-, $-C(0R^{13})_2$ or -CH(0H)-; W is -C(0)-, $-C(OR^{13})_2$ or $-C(R^{11})(OH)$ -; R^{11} is hydrogen atom or C_{1-3} alkyl; R^{12} is hydrogen or R^{14} (wherein R^{14} is physiologically hydrolyzable alkyl or M (wherein M is NH_4 , sodium, potassium, 1/2 calcium or a hydrate of lower alkyl amine, di-lower alkyl amine or tri-lower alkyl amine)); two R¹³ are independently primary or secondary C₁₋₆ alkyl; or two R^{13} together form $-(CH_2)_2$ or $-(CH_2)_3$; R^{17} and R^{18} are independently hydrogen or C_{1-3} alkyl; and R^5 is 10 hydrogen, C_{1-6} alkyl, C_{2+3} alkenyl, C_{3-6} cycloalkyl,

- 97 -

Ĩ

5

-{0} R⁹ (wherein R^9 is a hydrogen atom, C_{1-4} alkyl, C_{1-3} 15 alkoxy, fluoro, chloro, bromo or trifluoromethyl), phenyl-(CH₂)_m- (wherein m is 1,2 or 3), $-(CH_2)_n CH(CH_3)$ -phenyl or phenyl- $(CH_2)_n CH(CH_3)$ - (wherein n is 0,1 or 2).

16-115-42 (1593)

Declaration, Power Of Attorney and Petition

COPY

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

_____as

QUINOLINE TYPE MEVALONOLACTONES

the specification of which

1

□ is attached hereto.

🖄 was filed on <u>August 19, 1988</u>

Application Serial No. ____07/233,752

and amended on ____

□ was filed as PCT international application

Number _____

on _____.

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information material to the examination of this application in accordance with Section 1.56(a) of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under Section 119 of Title 35 United States Code, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application No.	Country	Day/Month/Year	Priority Claimed
207224/1987	Japan	20/8/87	. 🛛 Yes 🗆 No
15585/1988	Japan	26/1/88	. 🛛 Yes 🗆 No
Not Yet Allotted	Japan	3/8/88	. 🖾 Yes 🗆 No
	с. С		🗆 Yes 🗆 No

Page 2 of 3 Declaration

We (I) hereby claim the benefit under Section 120 of Title 35 United States Code, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Section 112 of Title 35 United States Code, We (I) acknowledge the duty to disclose material information as defined in Section 1.56(a) of Title 37 Code of Federal Regulations, which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented, abandoned)

And we (I) hereby appoint Norman F. Oblon, Registration Number 24,618, Stanley P. Fisher, Registration Number 24,344, Marvin J. Spivak, Registration Number 24,913, C. Irvin McClelland, Registration Number 21,124, Gregory J. Maier, Registration Number 25,599, Arthur I. Neustadt, Registration Number 24,854, Robert C. Miller, Registration Number 25,357, Richard D. Kelly, Registration Number 27,757, James D. Hamilton, Registration Number 28,421, Eckhard H. Kuesters, Registration Number 28,870, Robert T. Pous, Registration Number 29,099, Charles L. Gholz, Registration Number 26,395, Vincent J. Sunderdick, Registration Number 29,004, William E. Beaumont, Registration Number 30,996 and Steven B. Kelber, Registration Number 30,073, our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, FISHER, SPIVAK, McCLELLAND & MAIER, P.C., whose Post Office Address is: Crystal Square Five — Suite 400, 1755 South Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1 Yoshihiro Fujikawa-NAME OF FIRST SOLE INVENTOR

ikand Signature of Inventor

Signature of Inventor

October 3, 1988

Date

1

Residence.	Nissan.	Chemical	Indus	tries	Ltd.
tecordence.		Contraction of the second second second second			

Chuo	Kenkyusho,	722-1,	Tsuboi-cho	
Funal	bashi-shi,	Chiba-ke	en, Japan	16

Citizenship: _____ JAPAN

Post Office Address: same as above

Page 3 of 3 Declaration

6100 Residence: Nissan Chemical Industries Ltd. Mikio Suzuki NAME OF SECOND JOINT INVENTOR Chuo Kenkyusho, 722-1, Tsaboi-cho Funabashi-shi, Chiba-ken, Japan mikio Suzuki Citizenship: _____JAPAN Signature of Inventor Post Office Address: same as above October 3, 1988 Date 11 . 2 Hiroshi Iwasaki Residence: Nissan Chemical Industries Ltd. NAME OF THIRD JOINT INVENTOR Chuo Kenkyusho, 722-1, Tsuboi-cho Funabashi-shi, Chiba-ken, Japan Hiroshi Iwasaki Signature of Inventor Post Office Address: ____same as above October 3, 1988 Date 1.1 Mitsuaki Sakashita Residence: Nissan Chemical Industries Ltd. NAME OF FOURTH JOINT INVENTOR Seibutsukagaku Kenkyusho, 1470 Oaza-shiraoka, Shiraoka-machi Minamisaitama-gun, Saitama-ken, Japan JAPAN Citizenship: _ Signature of Inventor Post Office Address: same as above October 3, 1988 Date 11 32 2 1 Masaki Kitahara Residence: Nissan Chemical Industries Ltd. NAME OF FIFTH JOINT INVENTOR Seibutsukagaku Kenkyusho, 1470 Oaza-shiraoka, <u>Shiraoka-machi</u> Minamisaitama-gun, Saitama-ken, Japan Masaki Kitahare JAPAN Citizenship: _ Signature of Inventor Post Office Address: _____same as above

October 3, 1988

Date

-

Sawai Ex 1003 Page 105 of 175

	\$630.00-101 01 631092
1	AL ROOM
E	DEC IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
122	1990 5 A9-146-0 CONT
	TRADEMI
	NORABLE COMMISSIONER OF PATENTS & TRADEMARKS SHINGTON, D.C. 20231
	This is a request for filing a
L	X Continuation
ſ	application under 37 C.F.R. 1.60,
	of copending prior application Serial No.07/233,752 filed on <u>AUGUST 19, 1988</u> o
	YOSHIHIRO FUJIKAWA ET AL
	for QUINOLINE TYPE MEVALONOLACTONES
1, [\overline{X} Enclosed is a copy of the prior application as originally filed and an affidavit or declaration verify ing it as a true copy.
2. [Small Entity Status of this application has been established by a Verified Statement submitted in the parent application.
з.[X The filing fee is calculated below:
	CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT BELOW
	For Number Number Basic Fee filed extra Rate \$630.00
	Total Claims $1 - 20 = -0 \times 20 = 0$
	Independent Claims $\underline{1 - 3} = 0 \times \$ 60 = 0$
	Multiple Claim Fee \$ 200 = 0 Total Filing Fee = \$630
4. [The Commissioner is hereby authorized to charge any fees which may be required for the paper being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Account No. <u>15-0030</u> . A duplicate copy of this sheet is enclosed.
5 .[\underline{X} A check in the amount of $\underline{5.00}$ is enclosed.
2	Cancel Claims 2-9 and 11-23
,7.	A mend the specification by inserting before the first line the sentence:
1	This is a \underline{X} continuation, division, of application Serial No07/233,752, file on AUGUST 19, 1988
• 8. [New Drawings are enclosed.
9. [The prior application is assigned to:
: 	
	\sim /

Page 106 of 175

- 10. X The Power of Attorney in the prior application is to: Norman F. Oblon, Reg. No. 24,618; Marvin J. Spivak, Reg. No. 24,913; C. Irvin McClelland, Reg. No. 21,124; Gregory J. Maier, Reg. No. 25,599; Arthur I. Neustadt, Reg. No. 24,854; Robert C. Miller, Reg. No. 25,357; Richard D. Kelly, Reg. No. 27,757; James D. Hamilton, Reg. No. 28,421; Eckhard H. Kuesters, Reg. No. 28,870; Robert T. Pous, Reg. No. 29,099; Charles L. Gholz, Reg. No. 26,395; Vincent J. Sunderdick, Reg. No. 29,004; William E. Beaumont, Reg. No. 30,996; Steve B. Kelber, Reg. No. 30,073; Stuart D. Dwork, Reg. No. 31,103; Robert F. Gnuse, Reg. No. 27,295; and Jean-Paul Lavalleye, Reg. No. 31,451, all of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.
 - a. \mathbf{x} The power appears in the original papers of the prior application. (copy enclosed)
 - b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

c. Recognize as associate attorney and address all future communications to:

name, registration number and address

11. 🛛 A Preliminary Amendment is enclosed.

12. X Priority under §120 is enclosed.

Declaration of Steven B. Kelber is enclosed. White Advance Serial Number Postal Respectfully submitted, Card (postage prepaid) enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618 Steven B. Kelber Attorney of Record Registration No. 30,073

FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 521-5940

4/89

I

07 631092

6-0 CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: : YOSHIHIRO FUJIKAWA ET AL : GROUP ART UNIT: SERIAL NO: NEW RULE 60 CONTINUATION : FILED: HEREWITH : EXAMINER: FOR: QUINOLINE TYPE MEVALONOLACTONES :

DECLARATION

HONORABLE COMMISSIONER OF PATENTS & TRADEMARKS WASHINGTON, D.C. 20231

Sir:

I, STEVEN B. KELBER, declare the attached to be a true and accurate copy, as filed, of U.S. Patent Application Serial Number 07/233,752, filed on AUGUST 19, 1988.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618

Fourth Floor 1755 Jefferson Davis Highway Arlington, Virginia 22202 (703) 521-5940

Steven B. Kelber Registration No. 30,073

DOCKET NO 57146 98-0 CONT

IN RE APPLIC SERIAL FILED FOR

YOSHIHIRO FUJIKAWA ET AL

NEW RULE 60 PATENT APPLICATION (CONTINUATION) HEREWITH

QUINOLINE TYPE MEVALONOLACTONES

THE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, D.C. 20231

Sir:

1

FOURTH FLOOR

(703) 521-5940

ARLINGTON, VIRGINIA

1755 JEFFERSON DAVIS HIGHWAY

Transmitted herewith is an amendment in the above-identified application.

XX No additional fee is required.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- Small entity status of this application under 37 CFR 1.9 and 1.27 is established by a verified state- \square ment submitted herewith.
- Additional documents filed herewith:

The fee has been calculated as shown below.

(Col. 1) (Col. 2) (Col. 3) Highest No. Pre-viously Paid For Claims Present Extra Remaining After 5 . * * 40 -0-Total Minus . 1 *** 3 -0-Minus Indep First presentation of multiple dep. claim

Sma	Il Entity		Entity					
Rate	Addit. Fee	OR	Rate		Addit. Fee			
x =	s		×	=	\$	-0-		
x =	s		×	=	\$	-0-		
+ ' =	s		+	=	\$	-0-		
Total	s	OR	Tota	1	\$	-0-		

Other Than a Small

A check in the amount of \$ _____ <u>-0-</u> is attached.

. A duplicate copy of Charge \$ _____ to deposit account no. ______ this sheet is enclosed.

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account no. 15-0030 . A duplicate copy of xx] this sheet is enclosed.

Please charge any additional fees or credit any overpayment of fees required under 37 CFR 1.136 for any necessary extension of time to make the filing of the attached response timely to deposit account ×× no. <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon ATTORNEY OF RECORD REGISTRATION NO. 24,618

Steven B. Kelber Registration No. 30,073

If the entry in Column 2 is less than the entry in Column 1 write "0" in Column 3.
 If the "Highest Number Previously paid for " IN THIS SPACE is less than 20 write "20" in this space.
 If the "Highest Number Previously paid for " IN THIS SPACE is less than 3 write "3" in this space.

4/89

07 631092

49-146-0 CONT DUCKET NO.

IN HE APPLICATE SERIAL NO FILED FOR

YOSHIHIRO FUJIKAWA ET AL

NEW RULE 60 PATENT APPLICATION (CONTINUATION) HEREWITH

QUINOLINE TYPE MEVALONOLACTONES

THE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, D.C. 20231

Sir:

T

Transmitted herewith is an amendment in the above-identified application.

XX No additional fee is required.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- Small entity status of this application under 37 CFR 1.9 and 1.27 is established by a verified state- \square ment submitted herewith.
- Additional documents filed herewith:

he	fee	has	been	cal	cul	ate	ed	as	sho	wn	bel	ow.	

(Col. 1) (Col. 2) (Col. 3) Claims Remaining After Highest No. Pre-viously Paid For Present Extra 5 .. 40 -0-Minus Total ... 3 -0-1 Indep Minus = First presentation of multiple dep. claim

II Entity		Entity				
Addit. Fee	OR	Ra	ate	Add	dit. Fee	
s		×	=	\$	-0-	
s		x	=	\$	-0-	
s		+	=	s	-0-	
s	OR	Tota	al	\$	-0-	
	\$ \$ \$	Addit. Fee OR \$ \$ \$ \$	Addit. Fee OR Ri S X X S +	Addit. Fee OR Rate \$ OR x = \$ x = \$ + =	Addit. Fee OR Rate Addit. \$	

Other Than a Small

-0-A check in the amount of \$ _____ _ is attached.

____ to deposit account no. _______. A duplicate copy of Charge \$_ \square this sheet is enclosed.

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account no. 15.0030 . A duplicate copy of ×× this sheet is enclosed.

Please charge any additional fees or credit any overpayment of fees required under 37 CFR 1.136 for any necessary extension of time to make the filing of the attached response timely to deposit account ×× 15-0030 _. A duplicate copy of this sheet is enclosed. no. ____

OBLON, SPIVAK, McCLELLAND, MALER & NEUSTADT, P.C.

Norman F. Oblon ATTORNEY OF RECORD REGISTRATION NO. 24,618

Steven B. Kelber Registration No. 30,073

FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA (703) 521-5940

If the entry in Column 2 is less than the entry in Column 1 write "0" in Column 3.
 If the "Highest Number Previously paid for "IN THIS SPACE is less than 20 write "20" in this space.
 If the "Highest Number Previously paid for "IN THIS SPACE is less than 3 write "3" in this space.

4/89

		XX
	07 631092	ν ₈
ROO	• 49-146-0 C	ONT
DEC 19 1990 190	TRADEMARK OFFICE	۵ ۲
IN RE APPLICATION OF: :		
YOSHIHIRO FUJIKAWA ET AL :	GROUP ART UNIT:	
SERIAL NUMBER: NEW APPLICATION :	EXAMINER:	
FILED: HEREWITH :		

FOR: QUINOLINE TYPE MEVALONOLACTONES

PRELIMINARY AMENDMENT

HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

SIR:

In advance of prosecution of the above-captioned patent application, entry of the following amendments is respectfully requested.

IN THE CLAIMS:

Please cancel 1 and insert therefor new Claims 41-45 as follows:

RIZLO

-41. A compound of the formula

B 10



Wherein c-Pr is cyclopropyl, and Z is -COOH, COONa, COOR (wherein CI R is C₁₋₃ alkyl), or H0 Bunk K126 An anti-hyperlipidemia agent, containing the compound of the formula A as defined in Claim 41. R126 An anti-hyperlipoproteinemia agent containing the 43. compound of the formula A as defined in Claim 41. H RIRLO 44. An anti-atherosclerosis agent containing the compound of the formula A as defined in Claim 41. 5 R 126 45. method А for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis, which comprises administering an effective amount of the compound of formula A as defined in Claim 41 **REMARKS:** Claims 1-40 have been cancelled in favor of New Claims 41-45

in order to more clearly define the invention.

An action on the merits of the claims is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Ø BIC

Norman F. Oblon Registration No.: 24,618

Steven B. Kelber Registration No.: 30,073

1755 Jefferson Davis Highway Fourth Floor Arlington, Virginia 22202 Telephone: 703-521-5940

